Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,439000,elimination half-life,"The elimination half-life of meperidine in the fetus is 32.6 +/- 3.7 min when calculated from the urinary excretion rates, and 28.6 +/- 3.9 min when estimated from the plasma decay curve.",Urinary excretion of meperidine by the fetal lamb. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/439000/),min,32.6,3682,DB00454,Pethidine
,439000,elimination half-life,"The elimination half-life of meperidine in the fetus is 32.6 +/- 3.7 min when calculated from the urinary excretion rates, and 28.6 +/- 3.9 min when estimated from the plasma decay curve.",Urinary excretion of meperidine by the fetal lamb. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/439000/),min,28.6,3683,DB00454,Pethidine
,439000,renal clearance,The renal clearance of meperidine by the fetus ranged from 2.8 to 16.7 ml/min.,Urinary excretion of meperidine by the fetal lamb. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/439000/),[ml] / [min],2.8 to 16.7,3684,DB00454,Pethidine
,7205649,volume of distribution,The mean volume of distribution is 7.58 +/- 0.87 liters/kg; the mean elimination T 1/2 is 88.6 +/- 1.9 min and the plasma clearance is 59.3 +/- 1.4 ml/min/kg.,Methadone: radioimmunoassay and pharmacokinetics in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205649/),[l] / [kg],7.58,3860,DB00454,Pethidine
,7205649,elimination T 1/2,The mean volume of distribution is 7.58 +/- 0.87 liters/kg; the mean elimination T 1/2 is 88.6 +/- 1.9 min and the plasma clearance is 59.3 +/- 1.4 ml/min/kg.,Methadone: radioimmunoassay and pharmacokinetics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205649/),min,88.6,3861,DB00454,Pethidine
,7205649,plasma clearance,The mean volume of distribution is 7.58 +/- 0.87 liters/kg; the mean elimination T 1/2 is 88.6 +/- 1.9 min and the plasma clearance is 59.3 +/- 1.4 ml/min/kg.,Methadone: radioimmunoassay and pharmacokinetics in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205649/),[ml] / [kg·min],59.3,3862,DB00454,Pethidine
,9134513,elimination half-life,"Mean elimination half-life was 9.5 +/- 2.6 hours (range 5.7 to 12.7 hours), and volume of distribution at steady state was 17 +/- 9 L/kg (range 10.1 to 30.3 L/kg).",Pharmacokinetics of continuous infusion fentanyl in newborns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134513/),h,9.5,14676,DB00454,Pethidine
,9134513,volume of distribution at steady state,"Mean elimination half-life was 9.5 +/- 2.6 hours (range 5.7 to 12.7 hours), and volume of distribution at steady state was 17 +/- 9 L/kg (range 10.1 to 30.3 L/kg).",Pharmacokinetics of continuous infusion fentanyl in newborns. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134513/),[l] / [kg],17,14677,DB00454,Pethidine
,9134513,TBC,Mean TBC was 1154 +/- 494 ml/kg/hr (range 565 to 2000 ml/kg/hr).,Pharmacokinetics of continuous infusion fentanyl in newborns. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134513/),[ml] / [h·kg],1154,14678,DB00454,Pethidine
,282778,half-life,The half-life of oxazepam in the newborn averaged 22 hours as compared to 6.5 hours in the mothers.,Pharmacokinetics of oxazepam given during labour. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/282778/),h,22,20465,DB00454,Pethidine
,282778,half-life,The half-life of oxazepam in the newborn averaged 22 hours as compared to 6.5 hours in the mothers.,Pharmacokinetics of oxazepam given during labour. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/282778/),h,6.5,20466,DB00454,Pethidine
,7297025,systemic clearance,Meperidine systemic clearance rose from 1017 +/- 225 ml/min (mean +/- SD) to 1280 +/- 130 ml/min during phenytoin dosing (P less than 0.01).,Effect of phenytoin on meperidine clearance and normeperidine formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),[ml] / [min],1017,22547,DB00454,Pethidine
,7297025,systemic clearance,Meperidine systemic clearance rose from 1017 +/- 225 ml/min (mean +/- SD) to 1280 +/- 130 ml/min during phenytoin dosing (P less than 0.01).,Effect of phenytoin on meperidine clearance and normeperidine formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),[ml] / [min],1280,22548,DB00454,Pethidine
,7297025,elimination half-life,Meperidine elimination half-life fell from 6.4 +/- 1.0 hr to 4.3 +/- 0.4 hr during phenytoin dosing (P less than 0.05).,Effect of phenytoin on meperidine clearance and normeperidine formation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),h,6.4,22549,DB00454,Pethidine
,7297025,elimination half-life,Meperidine elimination half-life fell from 6.4 +/- 1.0 hr to 4.3 +/- 0.4 hr during phenytoin dosing (P less than 0.05).,Effect of phenytoin on meperidine clearance and normeperidine formation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),h,4.3,22550,DB00454,Pethidine
,7297025,Bioavailability,Bioavailability fell from 0.61 +/- 0.08 to 0.43 +/- 0.14 (P less than 0.07).,Effect of phenytoin on meperidine clearance and normeperidine formation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),,0.61,22551,DB00454,Pethidine
,7297025,Bioavailability,Bioavailability fell from 0.61 +/- 0.08 to 0.43 +/- 0.14 (P less than 0.07).,Effect of phenytoin on meperidine clearance and normeperidine formation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),,0.43,22552,DB00454,Pethidine
,7297025,area under the blood concentration-time curve from 0 to 24 hr,The normeperdine area under the blood concentration-time curve from 0 to 24 hr after intravenous meperidine rose from 385 +/- 105 ng/hr/ml-1 to 589 +/- 108 ng/hr/ml-1 during phenytoin dosing (P less than 0.01); after oral meperidine it rose from 592 +/- 50 ng/hr/ml-1 to 738 +/- 178 ng/hr/ml-1.,Effect of phenytoin on meperidine clearance and normeperidine formation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),[ng] / [h·ml],385,22553,DB00454,Pethidine
,7297025,area under the blood concentration-time curve from 0 to 24 hr,The normeperdine area under the blood concentration-time curve from 0 to 24 hr after intravenous meperidine rose from 385 +/- 105 ng/hr/ml-1 to 589 +/- 108 ng/hr/ml-1 during phenytoin dosing (P less than 0.01); after oral meperidine it rose from 592 +/- 50 ng/hr/ml-1 to 738 +/- 178 ng/hr/ml-1.,Effect of phenytoin on meperidine clearance and normeperidine formation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),[ng] / [h·ml],589,22554,DB00454,Pethidine
,7297025,area under the blood concentration-time curve from 0 to 24 hr,The normeperdine area under the blood concentration-time curve from 0 to 24 hr after intravenous meperidine rose from 385 +/- 105 ng/hr/ml-1 to 589 +/- 108 ng/hr/ml-1 during phenytoin dosing (P less than 0.01); after oral meperidine it rose from 592 +/- 50 ng/hr/ml-1 to 738 +/- 178 ng/hr/ml-1.,Effect of phenytoin on meperidine clearance and normeperidine formation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),[ng] / [h·ml],592,22555,DB00454,Pethidine
,7297025,area under the blood concentration-time curve from 0 to 24 hr,The normeperdine area under the blood concentration-time curve from 0 to 24 hr after intravenous meperidine rose from 385 +/- 105 ng/hr/ml-1 to 589 +/- 108 ng/hr/ml-1 during phenytoin dosing (P less than 0.01); after oral meperidine it rose from 592 +/- 50 ng/hr/ml-1 to 738 +/- 178 ng/hr/ml-1.,Effect of phenytoin on meperidine clearance and normeperidine formation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297025/),[ng] / [h·ml],738,22556,DB00454,Pethidine
,10530900,distribution t1/2,"The median values were similar to those reported for other species: distribution t1/2 = 2.5 min (range 1-11 min); elimination t1/2 = 43 min (range 17-108 min); apparent volume of distribution, 1474 ml/kg (range 830-9301 ml/kg); clearance, 33 ml/min/kg (range 12-57 ml/min/kg).",Pharmacokinetics of intravenously administered ketamine in southern elephant seals (Mirounga leonina). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530900/),min,2.5,28128,DB00454,Pethidine
,10530900,elimination t1/2,"The median values were similar to those reported for other species: distribution t1/2 = 2.5 min (range 1-11 min); elimination t1/2 = 43 min (range 17-108 min); apparent volume of distribution, 1474 ml/kg (range 830-9301 ml/kg); clearance, 33 ml/min/kg (range 12-57 ml/min/kg).",Pharmacokinetics of intravenously administered ketamine in southern elephant seals (Mirounga leonina). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530900/),min,43,28129,DB00454,Pethidine
,10530900,apparent volume of distribution,"The median values were similar to those reported for other species: distribution t1/2 = 2.5 min (range 1-11 min); elimination t1/2 = 43 min (range 17-108 min); apparent volume of distribution, 1474 ml/kg (range 830-9301 ml/kg); clearance, 33 ml/min/kg (range 12-57 ml/min/kg).",Pharmacokinetics of intravenously administered ketamine in southern elephant seals (Mirounga leonina). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530900/),[ml] / [kg],1474,28130,DB00454,Pethidine
,10530900,clearance,"The median values were similar to those reported for other species: distribution t1/2 = 2.5 min (range 1-11 min); elimination t1/2 = 43 min (range 17-108 min); apparent volume of distribution, 1474 ml/kg (range 830-9301 ml/kg); clearance, 33 ml/min/kg (range 12-57 ml/min/kg).",Pharmacokinetics of intravenously administered ketamine in southern elephant seals (Mirounga leonina). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530900/),[ml] / [kg·min],33,28131,DB00454,Pethidine
,2728269,critical,Correlation of plasma concentrations of the drug with its analgesic activity revealed a 'critical' concentration of pethidine of 0.4 micrograms/ml for complete analgesia; useful though not complete analgesia was achieved with concentrations above 0.2 micrograms/ml.,Pharmacokinetics of intramuscularly administered pethidine in dogs and the influence of anaesthesia and surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2728269/),[μg] / [ml],0.4,29298,DB00454,Pethidine
,1382879,Cmax,"The area under curve was 48% greater (P less than 0.01) and Cmax was higher in Group 2 than in Group 1, 145.8 +/- 42.2 vs 107 +/- 20.5 ng.",Clinical and pharmacokinetic aspects of the combination of meperidine and prilocaine for spinal anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1382879/),ng,145.8,29976,DB00454,Pethidine
,1382879,Cmax,"The area under curve was 48% greater (P less than 0.01) and Cmax was higher in Group 2 than in Group 1, 145.8 +/- 42.2 vs 107 +/- 20.5 ng.",Clinical and pharmacokinetic aspects of the combination of meperidine and prilocaine for spinal anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1382879/),ng,107,29977,DB00454,Pethidine
,2891328,maximum plasma concentrations,"Morphine appeared rapidly in plasma, and maximum plasma concentrations were usually detected 5 min after injection and averaged 33 ng.",Pharmacokinetics of epidural morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),ng,33,31927,DB00454,Pethidine
,2891328,terminal plasma half-life,"The terminal plasma half-life averaged 91 +/- 34 min and 87 +/- 27 min, respectively (mean +/- SEM).",Pharmacokinetics of epidural morphine and meperidine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,91,31928,DB00454,Pethidine
,2891328,terminal plasma half-life,"The terminal plasma half-life averaged 91 +/- 34 min and 87 +/- 27 min, respectively (mean +/- SEM).",Pharmacokinetics of epidural morphine and meperidine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,87,31929,DB00454,Pethidine
,2891328,Maximal plasma concentrations,Maximal plasma concentrations of meperidine were usually detected 10 or 15 min post-injection and averaged 196 +/- 29 ng.,Pharmacokinetics of epidural morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),ng,196,31930,DB00454,Pethidine
,2891328,terminal plasma half-life,The terminal plasma half-life averaged 124 +/- 26 min.,Pharmacokinetics of epidural morphine and meperidine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,124,31931,DB00454,Pethidine
,2891328,absorption half-life,"Morphine crossed the dura relatively slowly, and the absorption half-life across the dura averaged 22 min.",Pharmacokinetics of epidural morphine and meperidine in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,22,31932,DB00454,Pethidine
,2891328,absorption half-life,"In contrast, meperidine crossed the dura quickly, with an absorption half-life averaging 7.6 +/- 2.0 min.",Pharmacokinetics of epidural morphine and meperidine in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,7.6,31933,DB00454,Pethidine
,2891328,early half-life in CSF,"The early half-life in CSF averaged 73.3 +/- 11.5 min for morphine and 71.3 +/- 3.1 min for meperidine, and the late half-life averaged 369 +/- 113 min for morphine and 982 +/- 449 min for meperidine.",Pharmacokinetics of epidural morphine and meperidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,73.3,31934,DB00454,Pethidine
,2891328,early half-life in CSF,"The early half-life in CSF averaged 73.3 +/- 11.5 min for morphine and 71.3 +/- 3.1 min for meperidine, and the late half-life averaged 369 +/- 113 min for morphine and 982 +/- 449 min for meperidine.",Pharmacokinetics of epidural morphine and meperidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,71.3,31935,DB00454,Pethidine
,2891328,late half-life,"The early half-life in CSF averaged 73.3 +/- 11.5 min for morphine and 71.3 +/- 3.1 min for meperidine, and the late half-life averaged 369 +/- 113 min for morphine and 982 +/- 449 min for meperidine.",Pharmacokinetics of epidural morphine and meperidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,369,31936,DB00454,Pethidine
,2891328,late half-life,"The early half-life in CSF averaged 73.3 +/- 11.5 min for morphine and 71.3 +/- 3.1 min for meperidine, and the late half-life averaged 369 +/- 113 min for morphine and 982 +/- 449 min for meperidine.",Pharmacokinetics of epidural morphine and meperidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891328/),min,982,31937,DB00454,Pethidine
,3795304,TBC,TBC of this drug averaged 684 +/- 206 ml/min (mean +/- SD) and was highly correlated with ideal body weight (IBW) (r2 = 0.735; F = 27.75; n = 12; p less than 0.01).,The pharmacokinetics of meperidine in acute trauma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795304/),[ml] / [min],684,33708,DB00454,Pethidine
,9109962,half life,"In eight animals studied before surgery, the plasma levels of the drug decreased in a bi-exponential manner with a distributive half life of 3 mins and an elimination half life of 57.7 mins.",The influence of surgery and anaesthesia on the pharmacokinetics of pethidine in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109962/),min,3,34913,DB00454,Pethidine
,9109962,elimination half life,"In eight animals studied before surgery, the plasma levels of the drug decreased in a bi-exponential manner with a distributive half life of 3 mins and an elimination half life of 57.7 mins.",The influence of surgery and anaesthesia on the pharmacokinetics of pethidine in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109962/),min,57.7,34914,DB00454,Pethidine
,9109962,Total body clearance,Total body clearance was 17.7 ml/kg bwt/min.,The influence of surgery and anaesthesia on the pharmacokinetics of pethidine in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109962/),[ml] / [bwt·kg·min],17.7,34915,DB00454,Pethidine
,9109962,clearance rate,The remaining horses were investigated immediately after a period of anaesthesia and surgery and in these animals the drug exhibited smaller volumes of distribution (V1 cand Vdarea) and a significantly lower clearance rate of 12.8 ml/kg bwt/min in these animals.,The influence of surgery and anaesthesia on the pharmacokinetics of pethidine in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109962/),[ml] / [bwt·kg·min],12.8,34916,DB00454,Pethidine
,15509185,bioavailability,"Sustained-release tablets release the active ingredient over a period of 12 hours, reach peak concentrations after 4.9 hours and have a bioavailability of 87-95% compared with capsules.",Clinical pharmacology of tramadol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),%,87-95,35613,DB00454,Pethidine
,15509185,plasma protein binding,Tramadol is rapidly distributed in the body; plasma protein binding is about 20%.,Clinical pharmacology of tramadol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),%,20,35614,DB00454,Pethidine
,15509185,elimination half-life,The mean elimination half-life is about 6 hours.,Clinical pharmacology of tramadol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),h,6,35615,DB00454,Pethidine
,8280547,clearance,"After i.v. administration, the clearance of pethidine was mean 10.4 (SD 1.7) ml kg-1 min-1, volume of distribution at steady state 2.8 (0.6) litre kg-1 and elimination half-life 3.0 (0.5) h.",Pharmacokinetics of i.v. and rectal pethidine in children undergoing ophthalmic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280547/),[ml] / [kg·min],10.4,36786,DB00454,Pethidine
,8280547,volume of distribution at steady state,"After i.v. administration, the clearance of pethidine was mean 10.4 (SD 1.7) ml kg-1 min-1, volume of distribution at steady state 2.8 (0.6) litre kg-1 and elimination half-life 3.0 (0.5) h.",Pharmacokinetics of i.v. and rectal pethidine in children undergoing ophthalmic surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280547/),[l] / [kg],2.8,36787,DB00454,Pethidine
,8280547,elimination half-life,"After i.v. administration, the clearance of pethidine was mean 10.4 (SD 1.7) ml kg-1 min-1, volume of distribution at steady state 2.8 (0.6) litre kg-1 and elimination half-life 3.0 (0.5) h.",Pharmacokinetics of i.v. and rectal pethidine in children undergoing ophthalmic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280547/),h,3.0,36788,DB00454,Pethidine
,8280547,systemic bioavailability,The mean systemic bioavailability after rectal administration was approximately 55%.,Pharmacokinetics of i.v. and rectal pethidine in children undergoing ophthalmic surgery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280547/),%,55,36789,DB00454,Pethidine
,12492604,clearance,"Mean clearance in patients treated intravenously was 74.5 (95% CI 43.2, 128.3) and mean Vd was 2.4 l kg-1 (95% CI 2.0, 2.8).",The pharmacokinetics of ketobemidone in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492604/),,74.5,38514,DB00454,Pethidine
,12492604,Vd,"Mean clearance in patients treated intravenously was 74.5 (95% CI 43.2, 128.3) and mean Vd was 2.4 l kg-1 (95% CI 2.0, 2.8).",The pharmacokinetics of ketobemidone in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492604/),[l] / [kg],2.4,38515,DB00454,Pethidine
,12492604,"t1/2,z","t1/2,z also varied widely with a mean value of 4.41 h (95% CI 2.7, 7.0).",The pharmacokinetics of ketobemidone in critically ill patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492604/),h,4.41,38516,DB00454,Pethidine
,12492604,MRT,"The corresponding values for MRT were 5.4 and 3.3, 8.8.",The pharmacokinetics of ketobemidone in critically ill patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492604/),,5.4,38517,DB00454,Pethidine
,12492604,MRT,"The corresponding values for MRT were 5.4 and 3.3, 8.8.",The pharmacokinetics of ketobemidone in critically ill patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492604/),,3.3,38518,DB00454,Pethidine
,12492604,MRT,"The corresponding values for MRT were 5.4 and 3.3, 8.8.",The pharmacokinetics of ketobemidone in critically ill patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492604/),,8.8,38519,DB00454,Pethidine
,12492604,oral clearance (CL/F),"Mean oral clearance (CL/F) was 102 l h-1 (95% CI 82.7, 125.8), mean Vz/F was 11.2 l kg-1 (95% CI 9.7, 13.1) and mean t1/2,z was 6.0 (95% CI 4.9, 7.3) in orally treated patients.",The pharmacokinetics of ketobemidone in critically ill patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492604/),[l] / [h],102,38520,DB00454,Pethidine
,12492604,Vz/F,"Mean oral clearance (CL/F) was 102 l h-1 (95% CI 82.7, 125.8), mean Vz/F was 11.2 l kg-1 (95% CI 9.7, 13.1) and mean t1/2,z was 6.0 (95% CI 4.9, 7.3) in orally treated patients.",The pharmacokinetics of ketobemidone in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492604/),[l] / [kg],11.2,38521,DB00454,Pethidine
,12492604,"t1/2,z","Mean oral clearance (CL/F) was 102 l h-1 (95% CI 82.7, 125.8), mean Vz/F was 11.2 l kg-1 (95% CI 9.7, 13.1) and mean t1/2,z was 6.0 (95% CI 4.9, 7.3) in orally treated patients.",The pharmacokinetics of ketobemidone in critically ill patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492604/),,6.0,38522,DB00454,Pethidine
,12492604,Cmax,"Cmax showed a mean of 38 nmol l-1 (95% CI of 31, 47).",The pharmacokinetics of ketobemidone in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492604/),[nM] / [l],38,38523,DB00454,Pethidine
,7930474,extraction ratio,"At a perfusion rate of 10 ml/min, the extraction ratio of morphine in the normal liver was 0.67 +/- 0.18 and fell to 0.48 +/- 0.03 (p < 0.001) in the acutely damaged livers.",Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),,0.67,40601,DB00454,Pethidine
,7930474,extraction ratio,"At a perfusion rate of 10 ml/min, the extraction ratio of morphine in the normal liver was 0.67 +/- 0.18 and fell to 0.48 +/- 0.03 (p < 0.001) in the acutely damaged livers.",Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),,0.48,40602,DB00454,Pethidine
,7930474,hepatic clearance,The hepatic clearance of morphine fell from 6.7 +/- 0.2 ml/min in controls to 4.7 +/- 0.3 (p < 0.005) in the treated livers.,Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),[ml] / [min],6.7,40603,DB00454,Pethidine
,7930474,hepatic clearance,The hepatic clearance of morphine fell from 6.7 +/- 0.2 ml/min in controls to 4.7 +/- 0.3 (p < 0.005) in the treated livers.,Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),,4.7,40604,DB00454,Pethidine
,7930474,perfusion rates,Similar changes were seen at perfusion rates of 7 and 12 ml/min.,Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),[ml] / [min],7,40605,DB00454,Pethidine
,7930474,perfusion rates,Similar changes were seen at perfusion rates of 7 and 12 ml/min.,Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),[ml] / [min],12,40606,DB00454,Pethidine
,7930474,extraction ratio,"At a perfusion rate of 10 ml/min, the extraction ratio of pethidine was 0.97 +/- 0.01 in control livers and was reduced to 0.91 +/- 0.02 (p < 0.005) in damaged livers.",Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),,0.97,40607,DB00454,Pethidine
,7930474,extraction ratio,"At a perfusion rate of 10 ml/min, the extraction ratio of pethidine was 0.97 +/- 0.01 in control livers and was reduced to 0.91 +/- 0.02 (p < 0.005) in damaged livers.",Factors affecting the hepatic elimination of oxidized and of glucoronidated high clearance drugs following acute administration of carbon tetrachloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930474/),,0.91,40608,DB00454,Pethidine
less,7069580,C(0)/Cmin,"(b) As with monoexponential drugs, it is possible to obtain a larger tD by infusing the dose compared to that obtained with a bolus, if the value of C(0)/Cmin less than 2.5.",The effect of duration of intravenous infusion on maximum and threshold blood concentration for drugs exhibiting biexponential elimination kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069580/),,2.5,40697,DB00454,Pethidine
,8126759,tmax,"In healthy (n = 16) and post-operative (n = 16) goats, the parameters were, respectively: tmax 8.3 +/- 3.9 and 9.2 +/- 5.5 min, Vd 2.763 +/- 1.231 and 3.929 +/- 2.101 l/kg, Clb 0.125 +/- 0.036 and 0.087 +/- 0.025 l/kg/min, Ke 0.0563 +/- 0.0358 and 0.0271 +/- 0.0136 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),min,8.3,42761,DB00454,Pethidine
,8126759,tmax,"In healthy (n = 16) and post-operative (n = 16) goats, the parameters were, respectively: tmax 8.3 +/- 3.9 and 9.2 +/- 5.5 min, Vd 2.763 +/- 1.231 and 3.929 +/- 2.101 l/kg, Clb 0.125 +/- 0.036 and 0.087 +/- 0.025 l/kg/min, Ke 0.0563 +/- 0.0358 and 0.0271 +/- 0.0136 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),min,9.2,42762,DB00454,Pethidine
,8126759,Vd,"In healthy (n = 16) and post-operative (n = 16) goats, the parameters were, respectively: tmax 8.3 +/- 3.9 and 9.2 +/- 5.5 min, Vd 2.763 +/- 1.231 and 3.929 +/- 2.101 l/kg, Clb 0.125 +/- 0.036 and 0.087 +/- 0.025 l/kg/min, Ke 0.0563 +/- 0.0358 and 0.0271 +/- 0.0136 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),[l] / [kg],2.763,42763,DB00454,Pethidine
,8126759,Vd,"In healthy (n = 16) and post-operative (n = 16) goats, the parameters were, respectively: tmax 8.3 +/- 3.9 and 9.2 +/- 5.5 min, Vd 2.763 +/- 1.231 and 3.929 +/- 2.101 l/kg, Clb 0.125 +/- 0.036 and 0.087 +/- 0.025 l/kg/min, Ke 0.0563 +/- 0.0358 and 0.0271 +/- 0.0136 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),[l] / [kg],3.929,42764,DB00454,Pethidine
,8126759,Clb,"In healthy (n = 16) and post-operative (n = 16) goats, the parameters were, respectively: tmax 8.3 +/- 3.9 and 9.2 +/- 5.5 min, Vd 2.763 +/- 1.231 and 3.929 +/- 2.101 l/kg, Clb 0.125 +/- 0.036 and 0.087 +/- 0.025 l/kg/min, Ke 0.0563 +/- 0.0358 and 0.0271 +/- 0.0136 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),[l] / [kg·min],0.125,42765,DB00454,Pethidine
,8126759,Clb,"In healthy (n = 16) and post-operative (n = 16) goats, the parameters were, respectively: tmax 8.3 +/- 3.9 and 9.2 +/- 5.5 min, Vd 2.763 +/- 1.231 and 3.929 +/- 2.101 l/kg, Clb 0.125 +/- 0.036 and 0.087 +/- 0.025 l/kg/min, Ke 0.0563 +/- 0.0358 and 0.0271 +/- 0.0136 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),[l] / [kg·min],0.087,42766,DB00454,Pethidine
,8126759,Ke,"In healthy (n = 16) and post-operative (n = 16) goats, the parameters were, respectively: tmax 8.3 +/- 3.9 and 9.2 +/- 5.5 min, Vd 2.763 +/- 1.231 and 3.929 +/- 2.101 l/kg, Clb 0.125 +/- 0.036 and 0.087 +/- 0.025 l/kg/min, Ke 0.0563 +/- 0.0358 and 0.0271 +/- 0.0136 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),1/[min],0.0563,42767,DB00454,Pethidine
,8126759,Ke,"In healthy (n = 16) and post-operative (n = 16) goats, the parameters were, respectively: tmax 8.3 +/- 3.9 and 9.2 +/- 5.5 min, Vd 2.763 +/- 1.231 and 3.929 +/- 2.101 l/kg, Clb 0.125 +/- 0.036 and 0.087 +/- 0.025 l/kg/min, Ke 0.0563 +/- 0.0358 and 0.0271 +/- 0.0136 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),1/[min],0.0271,42768,DB00454,Pethidine
,8126759,Vd,"In this case, the parameters for healthy (n = 7) and post-operative (n = 13) goats were, respectively: Vd 5.212 +/- 1.992 and 5.085 +/- 2.288 l/kg, Clb 0.096 +/- 0.028 and 0.075 +/- 0.026 l/kg/min, beta 0.0211 +/- 0.0093 and 0.0160 +/- 0.0052 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),[l] / [kg],5.212,42769,DB00454,Pethidine
,8126759,Vd,"In this case, the parameters for healthy (n = 7) and post-operative (n = 13) goats were, respectively: Vd 5.212 +/- 1.992 and 5.085 +/- 2.288 l/kg, Clb 0.096 +/- 0.028 and 0.075 +/- 0.026 l/kg/min, beta 0.0211 +/- 0.0093 and 0.0160 +/- 0.0052 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),[l] / [kg],5.085,42770,DB00454,Pethidine
,8126759,Clb,"In this case, the parameters for healthy (n = 7) and post-operative (n = 13) goats were, respectively: Vd 5.212 +/- 1.992 and 5.085 +/- 2.288 l/kg, Clb 0.096 +/- 0.028 and 0.075 +/- 0.026 l/kg/min, beta 0.0211 +/- 0.0093 and 0.0160 +/- 0.0052 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),[l] / [kg·min],0.096,42771,DB00454,Pethidine
,8126759,Clb,"In this case, the parameters for healthy (n = 7) and post-operative (n = 13) goats were, respectively: Vd 5.212 +/- 1.992 and 5.085 +/- 2.288 l/kg, Clb 0.096 +/- 0.028 and 0.075 +/- 0.026 l/kg/min, beta 0.0211 +/- 0.0093 and 0.0160 +/- 0.0052 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),[l] / [kg·min],0.075,42772,DB00454,Pethidine
,8126759,beta,"In this case, the parameters for healthy (n = 7) and post-operative (n = 13) goats were, respectively: Vd 5.212 +/- 1.992 and 5.085 +/- 2.288 l/kg, Clb 0.096 +/- 0.028 and 0.075 +/- 0.026 l/kg/min, beta 0.0211 +/- 0.0093 and 0.0160 +/- 0.0052 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),1/[min],0.0211,42773,DB00454,Pethidine
,8126759,beta,"In this case, the parameters for healthy (n = 7) and post-operative (n = 13) goats were, respectively: Vd 5.212 +/- 1.992 and 5.085 +/- 2.288 l/kg, Clb 0.096 +/- 0.028 and 0.075 +/- 0.026 l/kg/min, beta 0.0211 +/- 0.0093 and 0.0160 +/- 0.0052 min-1.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),1/[min],0.0160,42774,DB00454,Pethidine
,8126759,Bioavailability,"Bioavailability of i.m. meperidine was 66.5 +/- 15.8% in healthy (n = 6) goats, but much higher in postoperative (n = 10) ones at 94.6 +/- 30.0%.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),%,66.5,42775,DB00454,Pethidine
,8126759,Bioavailability,"Bioavailability of i.m. meperidine was 66.5 +/- 15.8% in healthy (n = 6) goats, but much higher in postoperative (n = 10) ones at 94.6 +/- 30.0%.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),%,94.6,42776,DB00454,Pethidine
,8126759,elimination rate constant (K(ef)),"CSF kinetic parameters of i.m. meperidine for healthy (n = 7) and postoperative (n = 13) goats were: elimination rate constant (K(ef)) 0.0269 +/- 0.0131 and 0.0305 +/- 0.0177 min-1, peak CSF concentration time (Tmaxf) 15.9 +/- 5.0 and 17.0 +/- 6.9 min.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),1/[min],0.0269,42777,DB00454,Pethidine
,8126759,elimination rate constant (K(ef)),"CSF kinetic parameters of i.m. meperidine for healthy (n = 7) and postoperative (n = 13) goats were: elimination rate constant (K(ef)) 0.0269 +/- 0.0131 and 0.0305 +/- 0.0177 min-1, peak CSF concentration time (Tmaxf) 15.9 +/- 5.0 and 17.0 +/- 6.9 min.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),1/[min],0.0305,42778,DB00454,Pethidine
,8126759,peak CSF concentration time (Tmaxf),"CSF kinetic parameters of i.m. meperidine for healthy (n = 7) and postoperative (n = 13) goats were: elimination rate constant (K(ef)) 0.0269 +/- 0.0131 and 0.0305 +/- 0.0177 min-1, peak CSF concentration time (Tmaxf) 15.9 +/- 5.0 and 17.0 +/- 6.9 min.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),min,15.9,42779,DB00454,Pethidine
,8126759,peak CSF concentration time (Tmaxf),"CSF kinetic parameters of i.m. meperidine for healthy (n = 7) and postoperative (n = 13) goats were: elimination rate constant (K(ef)) 0.0269 +/- 0.0131 and 0.0305 +/- 0.0177 min-1, peak CSF concentration time (Tmaxf) 15.9 +/- 5.0 and 17.0 +/- 6.9 min.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),min,17.0,42780,DB00454,Pethidine
,8126759,K(ef),"For the i.v. dosed healthy (n = 6) and postoperative (n = 8) animals, K(ef) was 0.0408 +/- 0.0107, 0.0414 +/- 0.0123 min-1 and Tmaxf was 10.0 +/- 5.0 and 7.7 +/- 2.5 min, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),1/[min],0.0408,42781,DB00454,Pethidine
,8126759,K(ef),"For the i.v. dosed healthy (n = 6) and postoperative (n = 8) animals, K(ef) was 0.0408 +/- 0.0107, 0.0414 +/- 0.0123 min-1 and Tmaxf was 10.0 +/- 5.0 and 7.7 +/- 2.5 min, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),1/[min],0.0414,42782,DB00454,Pethidine
,8126759,Tmaxf,"For the i.v. dosed healthy (n = 6) and postoperative (n = 8) animals, K(ef) was 0.0408 +/- 0.0107, 0.0414 +/- 0.0123 min-1 and Tmaxf was 10.0 +/- 5.0 and 7.7 +/- 2.5 min, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),min,10.0,42783,DB00454,Pethidine
,8126759,Tmaxf,"For the i.v. dosed healthy (n = 6) and postoperative (n = 8) animals, K(ef) was 0.0408 +/- 0.0107, 0.0414 +/- 0.0123 min-1 and Tmaxf was 10.0 +/- 5.0 and 7.7 +/- 2.5 min, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): Pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126759/),min,7.7,42784,DB00454,Pethidine
,8040932,elimination rate constants,"After intramuscular (i.m., n = 16) and intravenous (i.v., n = 13) dosing (5 mg/kg), the elimination rate constants of meperidine in the effect compartment (Ke0) were 0.3744 +/- 0.2546 and 0.1123 +/- 0.0428 min-1, drug concentrations in the effect compartment generating half maximal analgesia (EC(50)) were 0.70 +/- 0.33 and 0.41 +/- 0.26 microgram/ml, the maximal effects (Emax) were 89.63 +/- 15.63 and 85.92 +/- 9.64%, and the Hill coefficients (S) were 2.61 +/- 1.21 and 2.37 +/- 1.15, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (II): Modelling. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040932/),1/[min],0.3744,45179,DB00454,Pethidine
,8040932,elimination rate constants,"After intramuscular (i.m., n = 16) and intravenous (i.v., n = 13) dosing (5 mg/kg), the elimination rate constants of meperidine in the effect compartment (Ke0) were 0.3744 +/- 0.2546 and 0.1123 +/- 0.0428 min-1, drug concentrations in the effect compartment generating half maximal analgesia (EC(50)) were 0.70 +/- 0.33 and 0.41 +/- 0.26 microgram/ml, the maximal effects (Emax) were 89.63 +/- 15.63 and 85.92 +/- 9.64%, and the Hill coefficients (S) were 2.61 +/- 1.21 and 2.37 +/- 1.15, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (II): Modelling. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040932/),1/[min],0.1123,45180,DB00454,Pethidine
,8040932,concentrations in the effect compartment generating half maximal analgesia (EC(50)),"After intramuscular (i.m., n = 16) and intravenous (i.v., n = 13) dosing (5 mg/kg), the elimination rate constants of meperidine in the effect compartment (Ke0) were 0.3744 +/- 0.2546 and 0.1123 +/- 0.0428 min-1, drug concentrations in the effect compartment generating half maximal analgesia (EC(50)) were 0.70 +/- 0.33 and 0.41 +/- 0.26 microgram/ml, the maximal effects (Emax) were 89.63 +/- 15.63 and 85.92 +/- 9.64%, and the Hill coefficients (S) were 2.61 +/- 1.21 and 2.37 +/- 1.15, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (II): Modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040932/),[μg] / [ml],0.70,45181,DB00454,Pethidine
,8040932,concentrations in the effect compartment generating half maximal analgesia (EC(50)),"After intramuscular (i.m., n = 16) and intravenous (i.v., n = 13) dosing (5 mg/kg), the elimination rate constants of meperidine in the effect compartment (Ke0) were 0.3744 +/- 0.2546 and 0.1123 +/- 0.0428 min-1, drug concentrations in the effect compartment generating half maximal analgesia (EC(50)) were 0.70 +/- 0.33 and 0.41 +/- 0.26 microgram/ml, the maximal effects (Emax) were 89.63 +/- 15.63 and 85.92 +/- 9.64%, and the Hill coefficients (S) were 2.61 +/- 1.21 and 2.37 +/- 1.15, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (II): Modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040932/),[μg] / [ml],0.41,45182,DB00454,Pethidine
,8040932,maximal effects (Emax),"After intramuscular (i.m., n = 16) and intravenous (i.v., n = 13) dosing (5 mg/kg), the elimination rate constants of meperidine in the effect compartment (Ke0) were 0.3744 +/- 0.2546 and 0.1123 +/- 0.0428 min-1, drug concentrations in the effect compartment generating half maximal analgesia (EC(50)) were 0.70 +/- 0.33 and 0.41 +/- 0.26 microgram/ml, the maximal effects (Emax) were 89.63 +/- 15.63 and 85.92 +/- 9.64%, and the Hill coefficients (S) were 2.61 +/- 1.21 and 2.37 +/- 1.15, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (II): Modelling. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040932/),%,89.63,45183,DB00454,Pethidine
,8040932,maximal effects (Emax),"After intramuscular (i.m., n = 16) and intravenous (i.v., n = 13) dosing (5 mg/kg), the elimination rate constants of meperidine in the effect compartment (Ke0) were 0.3744 +/- 0.2546 and 0.1123 +/- 0.0428 min-1, drug concentrations in the effect compartment generating half maximal analgesia (EC(50)) were 0.70 +/- 0.33 and 0.41 +/- 0.26 microgram/ml, the maximal effects (Emax) were 89.63 +/- 15.63 and 85.92 +/- 9.64%, and the Hill coefficients (S) were 2.61 +/- 1.21 and 2.37 +/- 1.15, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (II): Modelling. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040932/),%,85.92,45184,DB00454,Pethidine
,8040932,Hill coefficients (S),"After intramuscular (i.m., n = 16) and intravenous (i.v., n = 13) dosing (5 mg/kg), the elimination rate constants of meperidine in the effect compartment (Ke0) were 0.3744 +/- 0.2546 and 0.1123 +/- 0.0428 min-1, drug concentrations in the effect compartment generating half maximal analgesia (EC(50)) were 0.70 +/- 0.33 and 0.41 +/- 0.26 microgram/ml, the maximal effects (Emax) were 89.63 +/- 15.63 and 85.92 +/- 9.64%, and the Hill coefficients (S) were 2.61 +/- 1.21 and 2.37 +/- 1.15, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (II): Modelling. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040932/),,2.61,45185,DB00454,Pethidine
,8040932,Hill coefficients (S),"After intramuscular (i.m., n = 16) and intravenous (i.v., n = 13) dosing (5 mg/kg), the elimination rate constants of meperidine in the effect compartment (Ke0) were 0.3744 +/- 0.2546 and 0.1123 +/- 0.0428 min-1, drug concentrations in the effect compartment generating half maximal analgesia (EC(50)) were 0.70 +/- 0.33 and 0.41 +/- 0.26 microgram/ml, the maximal effects (Emax) were 89.63 +/- 15.63 and 85.92 +/- 9.64%, and the Hill coefficients (S) were 2.61 +/- 1.21 and 2.37 +/- 1.15, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (II): Modelling. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040932/),,2.37,45186,DB00454,Pethidine
,8040932,peak effect (Emax),"The predicted peak effect (Emax) of 64.44 +/- 14.64 and 66.02 +/- 11.51% were achieved at 14.7 +/- 7.4 and 8.5 +/- 2.2 min after i.m. and i.v. dosing, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (II): Modelling. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040932/),%,64.44,45187,DB00454,Pethidine
,8040932,peak effect (Emax),"The predicted peak effect (Emax) of 64.44 +/- 14.64 and 66.02 +/- 11.51% were achieved at 14.7 +/- 7.4 and 8.5 +/- 2.2 min after i.m. and i.v. dosing, respectively.",Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (II): Modelling. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040932/),%,66.02,45188,DB00454,Pethidine
,7094500,Vd(area),The peroperative Vd(area) was 5.9 +/- 2.6L/kg and the terminal half-life was 3.9 +/- 1.7 h.,"Patient-controlled analgesic therapy, Part III: pharmacokinetics and analgesic plasma concentrations of ketobemidone. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094500/),[l] / [kg],5.9,49577,DB00454,Pethidine
,7094500,terminal half-life,The peroperative Vd(area) was 5.9 +/- 2.6L/kg and the terminal half-life was 3.9 +/- 1.7 h.,"Patient-controlled analgesic therapy, Part III: pharmacokinetics and analgesic plasma concentrations of ketobemidone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094500/),h,3.9,49578,DB00454,Pethidine
,7094500,Vd(area),In the postoperative period Vd(area) decreased to 3.7 +/- 0.4L/kg and the terminal half-life to 2.1 +/- 0.4 h.,"Patient-controlled analgesic therapy, Part III: pharmacokinetics and analgesic plasma concentrations of ketobemidone. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094500/),[l] / [kg],3.7,49579,DB00454,Pethidine
,7094500,terminal half-life,In the postoperative period Vd(area) decreased to 3.7 +/- 0.4L/kg and the terminal half-life to 2.1 +/- 0.4 h.,"Patient-controlled analgesic therapy, Part III: pharmacokinetics and analgesic plasma concentrations of ketobemidone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094500/),h,2.1,49580,DB00454,Pethidine
,7094500,Clp,"Plasma clearance (Clp) did not change significantly, peroperative Clp being 18 +/- 4.3 ml/min/kg and postoperative Clp being 22 +/- 7.5 ml/min/kg.","Patient-controlled analgesic therapy, Part III: pharmacokinetics and analgesic plasma concentrations of ketobemidone. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094500/),[ml] / [kg·min],18,49581,DB00454,Pethidine
,7094500,Clp,"Plasma clearance (Clp) did not change significantly, peroperative Clp being 18 +/- 4.3 ml/min/kg and postoperative Clp being 22 +/- 7.5 ml/min/kg.","Patient-controlled analgesic therapy, Part III: pharmacokinetics and analgesic plasma concentrations of ketobemidone. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094500/),[ml] / [kg·min],22,49582,DB00454,Pethidine
,7094500,minimum effective concentration (MEC),Pseudosteady-state plasma concentrations of ketobemidone were established with a mean minimum effective concentration (MEC) of 25 +/- 11 ng/ml.,"Patient-controlled analgesic therapy, Part III: pharmacokinetics and analgesic plasma concentrations of ketobemidone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094500/),[ng] / [ml],25,49583,DB00454,Pethidine
,1469954,elimination half life (t1/2),The mean (+/- S.D.) elimination half life (t1/2) of pethidine was shorter in Caucasians (4.5 +/- 1.3 h) compared with Nepalese (6.3 +/- 1.6 h) and Chinese (8.1 +/- 3.1 h) (p < 0.01).,"Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1469954/),h,4.5,49855,DB00454,Pethidine
,1469954,elimination half life (t1/2),The mean (+/- S.D.) elimination half life (t1/2) of pethidine was shorter in Caucasians (4.5 +/- 1.3 h) compared with Nepalese (6.3 +/- 1.6 h) and Chinese (8.1 +/- 3.1 h) (p < 0.01).,"Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1469954/),h,6.3,49856,DB00454,Pethidine
,1469954,elimination half life (t1/2),The mean (+/- S.D.) elimination half life (t1/2) of pethidine was shorter in Caucasians (4.5 +/- 1.3 h) compared with Nepalese (6.3 +/- 1.6 h) and Chinese (8.1 +/- 3.1 h) (p < 0.01).,"Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1469954/),h,8.1,49857,DB00454,Pethidine
,1469954,plasma clearance,"The plasma clearance of pethidine was greater in Caucasians (14.2 +/- 4.8 ml.min-1.kg-1) than in Nepalese (12.6 +/- 2.9 ml.min-1.kg-1) and Chinese (10.0 +/- 2.9 ml.min-1.kg-1) (p < 0.05); yet the apparent renal clearance was similar (64.1 +/- 22.9, 86.7 +/- 44.5 and 61.4 +/- 30.1 ml.min-1.kg-1, respectively, for the Chinese (n = 6), Caucasian (n = 6) and Nepalese (n = 9) patients).","Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1469954/),[ml] / [kg·min],14.2,49858,DB00454,Pethidine
,1469954,plasma clearance,"The plasma clearance of pethidine was greater in Caucasians (14.2 +/- 4.8 ml.min-1.kg-1) than in Nepalese (12.6 +/- 2.9 ml.min-1.kg-1) and Chinese (10.0 +/- 2.9 ml.min-1.kg-1) (p < 0.05); yet the apparent renal clearance was similar (64.1 +/- 22.9, 86.7 +/- 44.5 and 61.4 +/- 30.1 ml.min-1.kg-1, respectively, for the Chinese (n = 6), Caucasian (n = 6) and Nepalese (n = 9) patients).","Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1469954/),[ml] / [kg·min],12.6,49859,DB00454,Pethidine
,1469954,plasma clearance,"The plasma clearance of pethidine was greater in Caucasians (14.2 +/- 4.8 ml.min-1.kg-1) than in Nepalese (12.6 +/- 2.9 ml.min-1.kg-1) and Chinese (10.0 +/- 2.9 ml.min-1.kg-1) (p < 0.05); yet the apparent renal clearance was similar (64.1 +/- 22.9, 86.7 +/- 44.5 and 61.4 +/- 30.1 ml.min-1.kg-1, respectively, for the Chinese (n = 6), Caucasian (n = 6) and Nepalese (n = 9) patients).","Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1469954/),[ml] / [kg·min],10.0,49860,DB00454,Pethidine
,1469954,apparent renal clearance,"The plasma clearance of pethidine was greater in Caucasians (14.2 +/- 4.8 ml.min-1.kg-1) than in Nepalese (12.6 +/- 2.9 ml.min-1.kg-1) and Chinese (10.0 +/- 2.9 ml.min-1.kg-1) (p < 0.05); yet the apparent renal clearance was similar (64.1 +/- 22.9, 86.7 +/- 44.5 and 61.4 +/- 30.1 ml.min-1.kg-1, respectively, for the Chinese (n = 6), Caucasian (n = 6) and Nepalese (n = 9) patients).","Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1469954/),[ml] / [kg·min],64.1,49861,DB00454,Pethidine
,1469954,apparent renal clearance,"The plasma clearance of pethidine was greater in Caucasians (14.2 +/- 4.8 ml.min-1.kg-1) than in Nepalese (12.6 +/- 2.9 ml.min-1.kg-1) and Chinese (10.0 +/- 2.9 ml.min-1.kg-1) (p < 0.05); yet the apparent renal clearance was similar (64.1 +/- 22.9, 86.7 +/- 44.5 and 61.4 +/- 30.1 ml.min-1.kg-1, respectively, for the Chinese (n = 6), Caucasian (n = 6) and Nepalese (n = 9) patients).","Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1469954/),[ml] / [kg·min],86.7,49862,DB00454,Pethidine
,1469954,apparent renal clearance,"The plasma clearance of pethidine was greater in Caucasians (14.2 +/- 4.8 ml.min-1.kg-1) than in Nepalese (12.6 +/- 2.9 ml.min-1.kg-1) and Chinese (10.0 +/- 2.9 ml.min-1.kg-1) (p < 0.05); yet the apparent renal clearance was similar (64.1 +/- 22.9, 86.7 +/- 44.5 and 61.4 +/- 30.1 ml.min-1.kg-1, respectively, for the Chinese (n = 6), Caucasian (n = 6) and Nepalese (n = 9) patients).","Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1469954/),[ml] / [kg·min],61.4,49863,DB00454,Pethidine
,7297021,terminal half-life (t1/2),"After intravenous administration with no control of urinary pH, meperidine blood levels declined triexponentially over 24 hr with a terminal half-life (t1/2) of 4.9 to 9.4 hr and a clearance of 472 to 686 ml/min.",Meperidine disposition in man: influence of urinary pH and route of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297021/),h,4.9 to 9.4,51188,DB00454,Pethidine
,7297021,clearance,"After intravenous administration with no control of urinary pH, meperidine blood levels declined triexponentially over 24 hr with a terminal half-life (t1/2) of 4.9 to 9.4 hr and a clearance of 472 to 686 ml/min.",Meperidine disposition in man: influence of urinary pH and route of administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297021/),[ml] / [min],472 to 686,51189,DB00454,Pethidine
,7297021,urinary recoveries,The 48-hr urinary recoveries of meperidine and normeperidine were about 7% and 12%.,Meperidine disposition in man: influence of urinary pH and route of administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297021/),%,7,51190,DB00454,Pethidine
,7297021,urinary recoveries,The 48-hr urinary recoveries of meperidine and normeperidine were about 7% and 12%.,Meperidine disposition in man: influence of urinary pH and route of administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297021/),%,12,51191,DB00454,Pethidine
,7297021,t1/2,Absorption after intramuscular injection was complete and followed a first-order process with t1/2 ranging from 7 to 13 min.,Meperidine disposition in man: influence of urinary pH and route of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297021/),min,7 to 13,51192,DB00454,Pethidine
,7297021,oral bioavailability,"In contrast, oral bioavailability was incomplete, ranging from 47% to 73%, and at a much slower rate, with peak concentrations being observed after about 1 hr.",Meperidine disposition in man: influence of urinary pH and route of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297021/),%,47,51193,DB00454,Pethidine
,7297021,oral bioavailability,"In contrast, oral bioavailability was incomplete, ranging from 47% to 73%, and at a much slower rate, with peak concentrations being observed after about 1 hr.",Meperidine disposition in man: influence of urinary pH and route of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297021/),%,73,51194,DB00454,Pethidine
,2354092,alpha,"Fitting of CSF concentrations to triexponential curves revealed mean (SD) alpha, beta and gamma half-lives of 13.2 (7.4), 54.9 (31.5) and 222.5 (100) min for morphine and 11.2 (2.4), 67.3 (49.9) and 619.3 (629.7) min for M6G.",Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354092/),min,13.2,54439,DB00454,Pethidine
,2354092,beta,"Fitting of CSF concentrations to triexponential curves revealed mean (SD) alpha, beta and gamma half-lives of 13.2 (7.4), 54.9 (31.5) and 222.5 (100) min for morphine and 11.2 (2.4), 67.3 (49.9) and 619.3 (629.7) min for M6G.",Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354092/),min,54.9,54440,DB00454,Pethidine
,2354092,beta,"Fitting of CSF concentrations to triexponential curves revealed mean (SD) alpha, beta and gamma half-lives of 13.2 (7.4), 54.9 (31.5) and 222.5 (100) min for morphine and 11.2 (2.4), 67.3 (49.9) and 619.3 (629.7) min for M6G.",Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354092/),min,11.2,54441,DB00454,Pethidine
,2354092,gamma half-lives,"Fitting of CSF concentrations to triexponential curves revealed mean (SD) alpha, beta and gamma half-lives of 13.2 (7.4), 54.9 (31.5) and 222.5 (100) min for morphine and 11.2 (2.4), 67.3 (49.9) and 619.3 (629.7) min for M6G.",Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354092/),min,222.5,54442,DB00454,Pethidine
,7039926,systemic bioavailability,"Following oral administration it is rapidly absorbed from the gastrointestinal tract, its systemic bioavailability being dose-dependent and ranging from 70 to 90%.",Clinical pharmacokinetics of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),%,70 to 90,56310,DB00454,Pethidine
,7039926,volume of distribution,It distributes rapidly and evenly throughout most tissues and fluids and has a volume of distribution of approximately 0.9L/kg.,Clinical pharmacokinetics of paracetamol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[l] / [kg],0.9,56311,DB00454,Pethidine
,7039926,plasma half-life,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),h,1.9 to 2.5,56312,DB00454,Pethidine
,7039926,total body clearance,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[ml] / [kg·min],4.5 to 5.5,56313,DB00454,Pethidine
,41039,recovery,"The amounts of these compounds recovered in the 48 h urine samples after intramuscular administration of pethidine (1.5 mg kg-1) to six healthy subjects varies with urinary pH values: the recovery from acidic urine (pH 5.0) is 15.2 to 52.0%, 6.7 to 12.9% and 0.2 to 2.3% of dose for pethidine, norpethidine and pethidine N-oxide respectively; in alkaline urine (pH 8.0) the values are 0.8 to 1.8%, 0.6 to 2.8% and 0.3 to 2.1% respectively.",The effects of physiocochemical properties of pethidine and its basic metabolites on their buccal absorption and renal elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/41039/),%,15.2 to 52.0,58452,DB00454,Pethidine
,41039,recovery,"The amounts of these compounds recovered in the 48 h urine samples after intramuscular administration of pethidine (1.5 mg kg-1) to six healthy subjects varies with urinary pH values: the recovery from acidic urine (pH 5.0) is 15.2 to 52.0%, 6.7 to 12.9% and 0.2 to 2.3% of dose for pethidine, norpethidine and pethidine N-oxide respectively; in alkaline urine (pH 8.0) the values are 0.8 to 1.8%, 0.6 to 2.8% and 0.3 to 2.1% respectively.",The effects of physiocochemical properties of pethidine and its basic metabolites on their buccal absorption and renal elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/41039/),%,6.7 to 12.9,58453,DB00454,Pethidine
,41039,recovery,"The amounts of these compounds recovered in the 48 h urine samples after intramuscular administration of pethidine (1.5 mg kg-1) to six healthy subjects varies with urinary pH values: the recovery from acidic urine (pH 5.0) is 15.2 to 52.0%, 6.7 to 12.9% and 0.2 to 2.3% of dose for pethidine, norpethidine and pethidine N-oxide respectively; in alkaline urine (pH 8.0) the values are 0.8 to 1.8%, 0.6 to 2.8% and 0.3 to 2.1% respectively.",The effects of physiocochemical properties of pethidine and its basic metabolites on their buccal absorption and renal elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/41039/),%,0.2 to 2.3,58454,DB00454,Pethidine
,41039,recovery,"The amounts of these compounds recovered in the 48 h urine samples after intramuscular administration of pethidine (1.5 mg kg-1) to six healthy subjects varies with urinary pH values: the recovery from acidic urine (pH 5.0) is 15.2 to 52.0%, 6.7 to 12.9% and 0.2 to 2.3% of dose for pethidine, norpethidine and pethidine N-oxide respectively; in alkaline urine (pH 8.0) the values are 0.8 to 1.8%, 0.6 to 2.8% and 0.3 to 2.1% respectively.",The effects of physiocochemical properties of pethidine and its basic metabolites on their buccal absorption and renal elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/41039/),%,0.8 to 1.8,58455,DB00454,Pethidine
,41039,recovery,"The amounts of these compounds recovered in the 48 h urine samples after intramuscular administration of pethidine (1.5 mg kg-1) to six healthy subjects varies with urinary pH values: the recovery from acidic urine (pH 5.0) is 15.2 to 52.0%, 6.7 to 12.9% and 0.2 to 2.3% of dose for pethidine, norpethidine and pethidine N-oxide respectively; in alkaline urine (pH 8.0) the values are 0.8 to 1.8%, 0.6 to 2.8% and 0.3 to 2.1% respectively.",The effects of physiocochemical properties of pethidine and its basic metabolites on their buccal absorption and renal elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/41039/),%,0.6 to 2.8,58456,DB00454,Pethidine
,41039,recovery,"The amounts of these compounds recovered in the 48 h urine samples after intramuscular administration of pethidine (1.5 mg kg-1) to six healthy subjects varies with urinary pH values: the recovery from acidic urine (pH 5.0) is 15.2 to 52.0%, 6.7 to 12.9% and 0.2 to 2.3% of dose for pethidine, norpethidine and pethidine N-oxide respectively; in alkaline urine (pH 8.0) the values are 0.8 to 1.8%, 0.6 to 2.8% and 0.3 to 2.1% respectively.",The effects of physiocochemical properties of pethidine and its basic metabolites on their buccal absorption and renal elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/41039/),%,0.3 to 2.1,58457,DB00454,Pethidine
,7291290,biological half life,"In comparison with the control group (4,2 h) the women in labour had a prolonged biological half life (7,5 h).",[The pharmacokinetics of pethidin (Dolcontral) of parturient and their new-borns (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291290/),h,"7,5",61164,DB00454,Pethidine
,7291290,half life,"The half life of pethidine was found to be prolonged (17,2 h) in newborns within two days after birth.",[The pharmacokinetics of pethidin (Dolcontral) of parturient and their new-borns (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291290/),h,"17,2",61165,DB00454,Pethidine
,2882701,elimination half-lives,"Morphine, pethidine and fentanyl have similar pharmacokinetic profiles with moderately long elimination half-lives (3 to 4 hours), large steady-state volumes of distribution (2 to 4 l/kg), and high hepatic clearances (10 to 20 ml/kg/min).",Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),h,3 to 4,62367,DB00454,Pethidine
,2882701,steady-state volumes of distribution,"Morphine, pethidine and fentanyl have similar pharmacokinetic profiles with moderately long elimination half-lives (3 to 4 hours), large steady-state volumes of distribution (2 to 4 l/kg), and high hepatic clearances (10 to 20 ml/kg/min).",Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),[l] / [kg],2 to 4,62368,DB00454,Pethidine
,2882701,hepatic clearances,"Morphine, pethidine and fentanyl have similar pharmacokinetic profiles with moderately long elimination half-lives (3 to 4 hours), large steady-state volumes of distribution (2 to 4 l/kg), and high hepatic clearances (10 to 20 ml/kg/min).",Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),[ml] / [kg·min],10 to 20,62369,DB00454,Pethidine
,2882701,terminal elimination half-life,Alfentanil has a shorter terminal elimination half-life (1 1/2 hours) because of a decreased steady-state volume of distribution (0.5 to 1 l/kg).,Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),h,1 1/2,62370,DB00454,Pethidine
,2882701,steady-state volume of distribution,Alfentanil has a shorter terminal elimination half-life (1 1/2 hours) because of a decreased steady-state volume of distribution (0.5 to 1 l/kg).,Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),[l] / [kg],0.5 to 1,62371,DB00454,Pethidine
,1671323,CSF/plasma concentration ratio,"No equilibrium was reached between the sufentanil concentration in CSF and plasma, but the CSF/plasma concentration ratio declined from approximately 140 at 2 h to about 15 at 10 h.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),,140,63189,DB00454,Pethidine
,1671323,CSF/plasma concentration ratio,"No equilibrium was reached between the sufentanil concentration in CSF and plasma, but the CSF/plasma concentration ratio declined from approximately 140 at 2 h to about 15 at 10 h.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),,15,63190,DB00454,Pethidine
,1671323,mean residence time (MRT),The mean residence time (MRT) of sufentanil in CSF was 0.92 +/- 0.08 h and in plasma was 6.8 +/- 0.6 h.,The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),h,0.92,63191,DB00454,Pethidine
,1671323,mean residence time (MRT),The mean residence time (MRT) of sufentanil in CSF was 0.92 +/- 0.08 h and in plasma was 6.8 +/- 0.6 h.,The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),h,6.8,63192,DB00454,Pethidine
,1671323,volume of distribution at steady state (Vss),"The volume of distribution at steady state (Vss) in the subarachnoid compartment was 1.54 +/- 0.39 ml/kg, and the clearance from the CSF was 27 +/- 5 microliters.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),[ml] / [kg],1.54,63193,DB00454,Pethidine
,1671323,clearance from the CSF,"The volume of distribution at steady state (Vss) in the subarachnoid compartment was 1.54 +/- 0.39 ml/kg, and the clearance from the CSF was 27 +/- 5 microliters.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),μl,27,63194,DB00454,Pethidine
,2878076,duration of action,"Alftentanil reaches its peak effect within 1 min after injection, and its duration of action is very short; at 2 times its MED50, 9r has a duration of action of 11 min.","Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878076/),min,11,70928,DB00454,Pethidine
,11887131,Peak heart rate,"Peak heart rate (91 beats/min for remifentanil vs 107 beats/min for meperidine, P <.01) and peak systolic blood pressure (131 mm Hg for remifentanil vs. 142 mm Hg for meperidine, P <.05) were significantly lower for the remifentanil group.",Remifentanil for use during conscious sedation in outpatient oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11887131/),[beats] / [min],91,73469,DB00454,Pethidine
,11887131,Peak heart rate,"Peak heart rate (91 beats/min for remifentanil vs 107 beats/min for meperidine, P <.01) and peak systolic blood pressure (131 mm Hg for remifentanil vs. 142 mm Hg for meperidine, P <.05) were significantly lower for the remifentanil group.",Remifentanil for use during conscious sedation in outpatient oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11887131/),[beats] / [min],107,73470,DB00454,Pethidine
,11887131,peak systolic blood pressure,"Peak heart rate (91 beats/min for remifentanil vs 107 beats/min for meperidine, P <.01) and peak systolic blood pressure (131 mm Hg for remifentanil vs. 142 mm Hg for meperidine, P <.05) were significantly lower for the remifentanil group.",Remifentanil for use during conscious sedation in outpatient oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11887131/),hg·mm,131,73471,DB00454,Pethidine
,11887131,peak systolic blood pressure,"Peak heart rate (91 beats/min for remifentanil vs 107 beats/min for meperidine, P <.01) and peak systolic blood pressure (131 mm Hg for remifentanil vs. 142 mm Hg for meperidine, P <.05) were significantly lower for the remifentanil group.",Remifentanil for use during conscious sedation in outpatient oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11887131/),hg·mm,142,73472,DB00454,Pethidine
,7294405,duration of anal,"Peridural meperidine HCl, 30-100 mg (n = 8), in 10 ml saline administered to patients with intractable pain gave a median duration of analgesia of 8 hours (range 4-20 hours) over periods ranging from 1-9 days.","Peridural meperidine in humans: analgesic response, pharmacokinetics, and transmission into CSF. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7294405/),h,8,76230,DB00454,Pethidine
,7294405,half-life,Systemic absorption of peridurally administered meperidine occurred with a half-life of 15-30 min and produced blood concentrations high enough to contribute to analgesia after approximately 20 min in the majority of patients.,"Peridural meperidine in humans: analgesic response, pharmacokinetics, and transmission into CSF. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7294405/),min,15-30,76231,DB00454,Pethidine
,2390424,elimination half-life,"Values of elimination half-life ranged from 13.1 to 44.7 h, systemic clearance from 1.02 to 1.63 l h-1 and volume of distribution from 1390 to 3940 l and these were similar to those obtained with bolus administration.",Pharmacokinetics of propofol when given by intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),h,13.1 to 44.7,76761,DB00454,Pethidine
,2390424,systemic clearance,"Values of elimination half-life ranged from 13.1 to 44.7 h, systemic clearance from 1.02 to 1.63 l h-1 and volume of distribution from 1390 to 3940 l and these were similar to those obtained with bolus administration.",Pharmacokinetics of propofol when given by intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),[l] / [h],1.02 to 1.63,76762,DB00454,Pethidine
,2390424,volume of distribution,"Values of elimination half-life ranged from 13.1 to 44.7 h, systemic clearance from 1.02 to 1.63 l h-1 and volume of distribution from 1390 to 3940 l and these were similar to those obtained with bolus administration.",Pharmacokinetics of propofol when given by intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),l,1390 to 3940,76763,DB00454,Pethidine
,2390424,o,"The large volume of distribution is consistent with the high octanol/blood partition coefficient, which was found to be 72.0.",Pharmacokinetics of propofol when given by intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),,72.0,76764,DB00454,Pethidine
,18165591,dynamic,"There were no significant differences among groups for mean (sd) dynamic pain scores in the postoperative care unit (2.2 [2.8], 2.5 [3.3], 1.6 [2.5], 2.6 [3.2], 2.7 [3.2] for groups C, M50, M100, R150, and M50R150, P = 0.50) or thereafter.",Disposition and clinical outcome after intraperitoneal meperidine and ropivacaine administration during laparoscopic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165591/),,2.2,79157,DB00454,Pethidine
,18165591,dynamic,"There were no significant differences among groups for mean (sd) dynamic pain scores in the postoperative care unit (2.2 [2.8], 2.5 [3.3], 1.6 [2.5], 2.6 [3.2], 2.7 [3.2] for groups C, M50, M100, R150, and M50R150, P = 0.50) or thereafter.",Disposition and clinical outcome after intraperitoneal meperidine and ropivacaine administration during laparoscopic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165591/),,2.5,79158,DB00454,Pethidine
,18165591,dynamic,"There were no significant differences among groups for mean (sd) dynamic pain scores in the postoperative care unit (2.2 [2.8], 2.5 [3.3], 1.6 [2.5], 2.6 [3.2], 2.7 [3.2] for groups C, M50, M100, R150, and M50R150, P = 0.50) or thereafter.",Disposition and clinical outcome after intraperitoneal meperidine and ropivacaine administration during laparoscopic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165591/),,1.6,79159,DB00454,Pethidine
,18165591,dynamic,"There were no significant differences among groups for mean (sd) dynamic pain scores in the postoperative care unit (2.2 [2.8], 2.5 [3.3], 1.6 [2.5], 2.6 [3.2], 2.7 [3.2] for groups C, M50, M100, R150, and M50R150, P = 0.50) or thereafter.",Disposition and clinical outcome after intraperitoneal meperidine and ropivacaine administration during laparoscopic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165591/),,2.6,79160,DB00454,Pethidine
,18165591,dynamic,"There were no significant differences among groups for mean (sd) dynamic pain scores in the postoperative care unit (2.2 [2.8], 2.5 [3.3], 1.6 [2.5], 2.6 [3.2], 2.7 [3.2] for groups C, M50, M100, R150, and M50R150, P = 0.50) or thereafter.",Disposition and clinical outcome after intraperitoneal meperidine and ropivacaine administration during laparoscopic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165591/),,2.7,79161,DB00454,Pethidine
,2891329,Maximum plasma morphine concentrations,"Maximum plasma morphine concentrations were found 5-10 min after injection, and averaged 4.5 +/- 1.1 ng.ml-1 (mean +/- SEM).",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),[ng] / [ml],4.5,81825,DB00454,Pethidine
,2891329,Maximum CSF morphine concentrations,"Maximum CSF morphine concentrations were considerably higher than maximum plasma concentrations, 6410 +/- 1290 ng.",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),ng,6410,81826,DB00454,Pethidine
,2891329,maximum plasma concentrations,"Maximum CSF morphine concentrations were considerably higher than maximum plasma concentrations, 6410 +/- 1290 ng.",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),ng,6410,81827,DB00454,Pethidine
,2891329,Maximum plasma concentrations,Maximum plasma concentrations of meperidine were also measured 5 or 10 min after injection and were low (36 +/- 9 ng.,Pharmacokinetics of intrathecal morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),ng,36,81828,DB00454,Pethidine
,2891329,maximum CSF concentrations,ml-1) compared with the maximum CSF concentrations (364 +/- 105 micrograms.ml-1).,Pharmacokinetics of intrathecal morphine and meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),[μg] / [ml],364,81829,DB00454,Pethidine
,2891329,half-life,"After a rapid initial decline for about 15 min after injection, the CSF concentrations decreased with a half-life of 89.8 +/- 16.1 min for morphine and 68.0 +/- 5.1 min for meperidine during the rest of the study period.",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),min,89.8,81830,DB00454,Pethidine
,2891329,half-life,"After a rapid initial decline for about 15 min after injection, the CSF concentrations decreased with a half-life of 89.8 +/- 16.1 min for morphine and 68.0 +/- 5.1 min for meperidine during the rest of the study period.",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),min,68.0,81831,DB00454,Pethidine
,2891329,initial volume of distribution in CSF,"The initial volume of distribution in CSF was similar for both drugs, or 22 +/- 8 ml for morphine and 18 +/- 5 ml for meperidine.",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),ml,22,81832,DB00454,Pethidine
,2891329,initial volume of distribution in CSF,"The initial volume of distribution in CSF was similar for both drugs, or 22 +/- 8 ml for morphine and 18 +/- 5 ml for meperidine.",Pharmacokinetics of intrathecal morphine and meperidine in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891329/),ml,18,81833,DB00454,Pethidine
,688732,half-time for transfer,The mean half-time for transfer was 6.8 +/- 0.9 min.,Kinetics of acetaminophen absorption and gastric emptying in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688732/),min,6.8,83058,DB00454,Pethidine
,2748192,delay time,There was a mean (S.D.) delay time of 12.7 (9.6) h before minimum effective blood fentanyl concentrations (MEC) were obtained from the systems and pseudo-steady state was reached between 36 and 48 h.,The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748192/),h,12.7,84211,DB00454,Pethidine
,2748192,decay time,There was a decay time of 16.1 (7.1) h after the systems were removed for the blood fentanyl concentration to decrease to less than the mean MEC for the control of postoperative pain.,The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748192/),h,16.1,84212,DB00454,Pethidine
,32998730,volume of distribution at steady state,"The volume of distribution at steady state and systemic clearance (mean ± SD) ranged from 0.829 ± 0.138-1.58 ± 0.280 L/kg and 18.0 ± 1.4-22.8 ± 3.60 mL/min/kg, respectively for 0.5-1.0 mg/kg doses.",Meperidine pharmacokinetics and effects on physiologic parameters and thermal threshold following intravenous administration of three doses to horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32998730/),[l] / [kg],0.829,89164,DB00454,Pethidine
,32998730,systemic clearance,"The volume of distribution at steady state and systemic clearance (mean ± SD) ranged from 0.829 ± 0.138-1.58 ± 0.280 L/kg and 18.0 ± 1.4-22.8 ± 3.60 mL/min/kg, respectively for 0.5-1.0 mg/kg doses.",Meperidine pharmacokinetics and effects on physiologic parameters and thermal threshold following intravenous administration of three doses to horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32998730/),[l] / [kg],1.58,89165,DB00454,Pethidine
,32998730,systemic clearance,"The volume of distribution at steady state and systemic clearance (mean ± SD) ranged from 0.829 ± 0.138-1.58 ± 0.280 L/kg and 18.0 ± 1.4-22.8 ± 3.60 mL/min/kg, respectively for 0.5-1.0 mg/kg doses.",Meperidine pharmacokinetics and effects on physiologic parameters and thermal threshold following intravenous administration of three doses to horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32998730/),[ml] / [kg·min],18.0,89166,DB00454,Pethidine
,32998730,systemic clearance,"The volume of distribution at steady state and systemic clearance (mean ± SD) ranged from 0.829 ± 0.138-1.58 ± 0.280 L/kg and 18.0 ± 1.4-22.8 ± 3.60 mL/min/kg, respectively for 0.5-1.0 mg/kg doses.",Meperidine pharmacokinetics and effects on physiologic parameters and thermal threshold following intravenous administration of three doses to horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32998730/),[ml] / [kg·min],22.8,89167,DB00454,Pethidine
,7978421,maximum arterial blood concentrations,"After an intravenous (i.v.) bolus of 100, 200, or 300 mg meperidine HCl, the maximum arterial blood concentrations (mean +/- SD) were 27.8 +/- 4.6, 66.8 +/- 13.3, and 114.5 +/- 23.1 micrograms/mL, respectively, and coronary sinus blood concentrations were 2.7 +/- 1.0, 7 +/- 1.5, and 13.7 +/- 2.5 micrograms/mL, respectively.",The pharmacokinetics of meperidine in the myocardium of conscious sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978421/),[μg] / [ml],27.8,90108,DB00454,Pethidine
,7978421,maximum arterial blood concentrations,"After an intravenous (i.v.) bolus of 100, 200, or 300 mg meperidine HCl, the maximum arterial blood concentrations (mean +/- SD) were 27.8 +/- 4.6, 66.8 +/- 13.3, and 114.5 +/- 23.1 micrograms/mL, respectively, and coronary sinus blood concentrations were 2.7 +/- 1.0, 7 +/- 1.5, and 13.7 +/- 2.5 micrograms/mL, respectively.",The pharmacokinetics of meperidine in the myocardium of conscious sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978421/),[μg] / [ml],66.8,90109,DB00454,Pethidine
,7978421,maximum arterial blood concentrations,"After an intravenous (i.v.) bolus of 100, 200, or 300 mg meperidine HCl, the maximum arterial blood concentrations (mean +/- SD) were 27.8 +/- 4.6, 66.8 +/- 13.3, and 114.5 +/- 23.1 micrograms/mL, respectively, and coronary sinus blood concentrations were 2.7 +/- 1.0, 7 +/- 1.5, and 13.7 +/- 2.5 micrograms/mL, respectively.",The pharmacokinetics of meperidine in the myocardium of conscious sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978421/),[μg] / [ml],114.5,90110,DB00454,Pethidine
,7978421,coronary sinus blood concentrations,"After an intravenous (i.v.) bolus of 100, 200, or 300 mg meperidine HCl, the maximum arterial blood concentrations (mean +/- SD) were 27.8 +/- 4.6, 66.8 +/- 13.3, and 114.5 +/- 23.1 micrograms/mL, respectively, and coronary sinus blood concentrations were 2.7 +/- 1.0, 7 +/- 1.5, and 13.7 +/- 2.5 micrograms/mL, respectively.",The pharmacokinetics of meperidine in the myocardium of conscious sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978421/),[μg] / [ml],2.7,90111,DB00454,Pethidine
,7978421,coronary sinus blood concentrations,"After an intravenous (i.v.) bolus of 100, 200, or 300 mg meperidine HCl, the maximum arterial blood concentrations (mean +/- SD) were 27.8 +/- 4.6, 66.8 +/- 13.3, and 114.5 +/- 23.1 micrograms/mL, respectively, and coronary sinus blood concentrations were 2.7 +/- 1.0, 7 +/- 1.5, and 13.7 +/- 2.5 micrograms/mL, respectively.",The pharmacokinetics of meperidine in the myocardium of conscious sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978421/),[μg] / [ml],7,90112,DB00454,Pethidine
,7978421,coronary sinus blood concentrations,"After an intravenous (i.v.) bolus of 100, 200, or 300 mg meperidine HCl, the maximum arterial blood concentrations (mean +/- SD) were 27.8 +/- 4.6, 66.8 +/- 13.3, and 114.5 +/- 23.1 micrograms/mL, respectively, and coronary sinus blood concentrations were 2.7 +/- 1.0, 7 +/- 1.5, and 13.7 +/- 2.5 micrograms/mL, respectively.",The pharmacokinetics of meperidine in the myocardium of conscious sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978421/),[μg] / [ml],13.7,90113,DB00454,Pethidine
,7978421,maximum rates of uptake (influxes),"Net uptake of meperidine into the myocardium occurred during the first minute and the maximum rates of uptake (influxes) were 5.1 +/- 2.6, 15.1 +/- 4.6, and 27.5 +/- 8.7 mg/min.",The pharmacokinetics of meperidine in the myocardium of conscious sheep. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978421/),[mg] / [min],5.1,90114,DB00454,Pethidine
,7978421,maximum rates of uptake (influxes),"Net uptake of meperidine into the myocardium occurred during the first minute and the maximum rates of uptake (influxes) were 5.1 +/- 2.6, 15.1 +/- 4.6, and 27.5 +/- 8.7 mg/min.",The pharmacokinetics of meperidine in the myocardium of conscious sheep. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978421/),[mg] / [min],15.1,90115,DB00454,Pethidine
,7978421,maximum rates of uptake (influxes),"Net uptake of meperidine into the myocardium occurred during the first minute and the maximum rates of uptake (influxes) were 5.1 +/- 2.6, 15.1 +/- 4.6, and 27.5 +/- 8.7 mg/min.",The pharmacokinetics of meperidine in the myocardium of conscious sheep. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978421/),[mg] / [min],27.5,90116,DB00454,Pethidine
,3379669,distribution half-life,Plasma concentrations of the drug exhibited a rapid biexponential pattern of decline with an average distribution half-life of 0.99 min and an elimination half-life of 12.8 min.,The correlation of the thermal and mechanical antinociceptive activity of pethidine hydrochloride with plasma concentrations of the drug in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379669/),min,0.99,94640,DB00454,Pethidine
,3379669,elimination half-life,Plasma concentrations of the drug exhibited a rapid biexponential pattern of decline with an average distribution half-life of 0.99 min and an elimination half-life of 12.8 min.,The correlation of the thermal and mechanical antinociceptive activity of pethidine hydrochloride with plasma concentrations of the drug in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379669/),min,12.8,94641,DB00454,Pethidine
,10620557,blood clearance,"During hemodialysis, normeperidine average blood clearance was 73 mL/min, average plasma clearance was 50 mL/min, and average percentage of plasma extraction was 24%.",Successful treatment of normeperidine neurotoxicity by hemodialysis. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10620557/),[ml] / [min],73,96273,DB00454,Pethidine
,10620557,plasma clearance,"During hemodialysis, normeperidine average blood clearance was 73 mL/min, average plasma clearance was 50 mL/min, and average percentage of plasma extraction was 24%.",Successful treatment of normeperidine neurotoxicity by hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10620557/),[ml] / [min],50,96274,DB00454,Pethidine
,10620557,percentage of plasma extraction,"During hemodialysis, normeperidine average blood clearance was 73 mL/min, average plasma clearance was 50 mL/min, and average percentage of plasma extraction was 24%.",Successful treatment of normeperidine neurotoxicity by hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10620557/),%,24,96275,DB00454,Pethidine
,7067310,Vd area,Mean +/- SD for peroperative Vd area was 4.3 +/- 1.7L/kg and for the elimination half-life was 6.1 +/- 3.6h.,Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7067310/),[l] / [kg],4.3,96430,DB00454,Pethidine
,7067310,elimination half-life,Mean +/- SD for peroperative Vd area was 4.3 +/- 1.7L/kg and for the elimination half-life was 6.1 +/- 3.6h.,Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7067310/),h,6.1,96431,DB00454,Pethidine
,7067310,Vdarea,In the postoperative period Vdarea was 3.2 +/- 0.8L/kg and the elimination half-life was 3.2 +/- 1.4h.,Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7067310/),[l] / [kg],3.2,96432,DB00454,Pethidine
,7067310,elimination half-life,In the postoperative period Vdarea was 3.2 +/- 0.8L/kg and the elimination half-life was 3.2 +/- 1.4h.,Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7067310/),h,3.2,96433,DB00454,Pethidine
,7067310,Plasma clearance,Plasma clearance increased from a peroperative value of 8.9 +/- 1.9 ml/min/kg to a postoperative value of 12 +/- 3.0 ml/min/kg.,Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7067310/),[ml] / [kg·min],8.9,96434,DB00454,Pethidine
,7067310,Plasma clearance,Plasma clearance increased from a peroperative value of 8.9 +/- 1.9 ml/min/kg to a postoperative value of 12 +/- 3.0 ml/min/kg.,Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7067310/),[ml] / [kg·min],12,96435,DB00454,Pethidine
,7067310,fraction of unbound pethi,The fraction of unbound pethidine was significantly reduced postoperatively - from 0.26 +/- 0.10 (peroperatively) to 0.18 +/- 0.10 (3 to 5 days later).,Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7067310/),,0.26,96436,DB00454,Pethidine
,7067310,fraction of unbound pethi,The fraction of unbound pethidine was significantly reduced postoperatively - from 0.26 +/- 0.10 (peroperatively) to 0.18 +/- 0.10 (3 to 5 days later).,Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7067310/),,0.18,96437,DB00454,Pethidine
greater,10676987,recoveries,The recoveries of tramadol and meperidine (internal standard) were greater than 88%.,Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),%,88,99736,DB00454,Pethidine
,10676987,limit of detection,The limit of detection was 8 ng/ml of plasma based on signal-to-noise ratio of 3.,Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),[ng] / [ml],8,99737,DB00454,Pethidine
,10676987,signal-to-noise ratio,The limit of detection was 8 ng/ml of plasma based on signal-to-noise ratio of 3.,Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),,3,99738,DB00454,Pethidine
,10676987,distribution,The distribution and elimination half-lives in humans were 1.02 and 141.9 min.,Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),min,1.02,99739,DB00454,Pethidine
,10676987,elimination half-lives,The distribution and elimination half-lives in humans were 1.02 and 141.9 min.,Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),min,141.9,99740,DB00454,Pethidine
,10676987,distribution,"The distribution and elimination half-lives in rabbits were 7.31 and 63.2 min, respectively.",Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),min,7.31,99741,DB00454,Pethidine
,10676987,elimination half-lives,"The distribution and elimination half-lives in rabbits were 7.31 and 63.2 min, respectively.",Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),min,63.2,99742,DB00454,Pethidine
,3169113,tmax,"Pethidine appeared more slowly in plasma after intrathecal than after epidural administration (tmax 2.3 h and 14 min, respectively), but systemic bioavailability was similar.",CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),h,2.3,102099,DB00454,Pethidine
,3169113,tmax,"Pethidine appeared more slowly in plasma after intrathecal than after epidural administration (tmax 2.3 h and 14 min, respectively), but systemic bioavailability was similar.",CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),min,14,102100,DB00454,Pethidine
,3169113,maximal CSF/plasma concentration ratio,"The maximal CSF/plasma concentration ratio was 6000 to 45,000 after intrathecal administration but was only 26 to 97 after the epidural route.",CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),,"6000 to 45,000",102101,DB00454,Pethidine
,3169113,maximal CSF/plasma concentration ratio,"The maximal CSF/plasma concentration ratio was 6000 to 45,000 after intrathecal administration but was only 26 to 97 after the epidural route.",CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),,26 to 97,102102,DB00454,Pethidine
,3169113,CSF/plasma concentration ratios,"Pethidine was rapidly distributed in CSF; nine to ten h after the intrathecal and epidural injections the CSF/plasma concentration ratios were 12 to 89 and 2 to 33, respectively.",CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),,12 to 89,102103,DB00454,Pethidine
,3169113,CSF/plasma concentration ratios,"Pethidine was rapidly distributed in CSF; nine to ten h after the intrathecal and epidural injections the CSF/plasma concentration ratios were 12 to 89 and 2 to 33, respectively.",CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),,2 to 33,102104,DB00454,Pethidine
,3169113,bioavailability,The calculated bioavailability in CSF of epidural pethidine was 10.3%.,CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),%,10.3,102105,DB00454,Pethidine
,3169113,terminal elimination half-life,The terminal elimination half-life of pethidine was 6.0 h (CSF) and 5.4 h (plasma) after intrathecal administration and 8.6 h (CSF) and 8.8 h (plasma) after epidural injection.,CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),h,6.0,102106,DB00454,Pethidine
,3169113,terminal elimination half-life,The terminal elimination half-life of pethidine was 6.0 h (CSF) and 5.4 h (plasma) after intrathecal administration and 8.6 h (CSF) and 8.8 h (plasma) after epidural injection.,CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),h,5.4,102107,DB00454,Pethidine
,3169113,terminal elimination half-life,The terminal elimination half-life of pethidine was 6.0 h (CSF) and 5.4 h (plasma) after intrathecal administration and 8.6 h (CSF) and 8.8 h (plasma) after epidural injection.,CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),h,8.6,102108,DB00454,Pethidine
,3169113,terminal elimination half-life,The terminal elimination half-life of pethidine was 6.0 h (CSF) and 5.4 h (plasma) after intrathecal administration and 8.6 h (CSF) and 8.8 h (plasma) after epidural injection.,CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),h,8.8,102109,DB00454,Pethidine
,3169113,volume of distribution,The volume of distribution of unchanged pethidine in the subarachnoid space was 13 ml.kg-1 and clearance from the CSF was 15 microliters.,CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),[ml] / [kg],13,102110,DB00454,Pethidine
,3169113,clearance from the CSF,The volume of distribution of unchanged pethidine in the subarachnoid space was 13 ml.kg-1 and clearance from the CSF was 15 microliters.,CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),μl,15,102111,DB00454,Pethidine
,3169113,maximum CSF norpethidine,"In all patients receiving intrathecal pethidine and in some patients after epidural pethidine, CSF norpethidine concentrations were higher than those in plasma; the maximum CSF norpethidine was 102 to 1211 ng.",CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169113/),ng,102 to 1211,102112,DB00454,Pethidine
,3797808,steady-state distribution volume,The meperidine steady-state distribution volume (about 2 1/kg) during both the acute and the convalescent studies was about half the distribution volume reported in the literature for meperidine in healthy subjects.,Meperidine disposition in burn patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3797808/),[1] / [kg],2,105606,DB00454,Pethidine
,3797808,clearance,"The meperidine clearance in burn patients (acute, 420 ml/min and convalescent, 600 ml/min) was lower than would be anticipated in the presence of known marked increases in hepatic blood flow in burn patients.",Meperidine disposition in burn patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3797808/),[ml] / [min],420,105607,DB00454,Pethidine
,3797808,clearance,"The meperidine clearance in burn patients (acute, 420 ml/min and convalescent, 600 ml/min) was lower than would be anticipated in the presence of known marked increases in hepatic blood flow in burn patients.",Meperidine disposition in burn patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3797808/),[ml] / [min],600,105608,DB00454,Pethidine
,33242227,terminal half-life (T1/2 ),"Meperidine terminal half-life (T1/2 ), maximal plasma concentrations, and time to maximal concentration were 186 ± 59 and 164 ± 56 minutes, 265.7 ± 47.2 and 243.1 ± 80.1 ng/mL at 17 ± 6, and 24 ± 13 minutes for IM at subcutaneous administration, respectively.",Pharmacokinetics and pharmacodynamics of meperidine after intramuscular and subcutaneous administration in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33242227/),min,186,106852,DB00454,Pethidine
,33242227,maximal plasma concentrations,"Meperidine terminal half-life (T1/2 ), maximal plasma concentrations, and time to maximal concentration were 186 ± 59 and 164 ± 56 minutes, 265.7 ± 47.2 and 243.1 ± 80.1 ng/mL at 17 ± 6, and 24 ± 13 minutes for IM at subcutaneous administration, respectively.",Pharmacokinetics and pharmacodynamics of meperidine after intramuscular and subcutaneous administration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33242227/),min,164,106853,DB00454,Pethidine
,33242227,maximal plasma concentrations,"Meperidine terminal half-life (T1/2 ), maximal plasma concentrations, and time to maximal concentration were 186 ± 59 and 164 ± 56 minutes, 265.7 ± 47.2 and 243.1 ± 80.1 ng/mL at 17 ± 6, and 24 ± 13 minutes for IM at subcutaneous administration, respectively.",Pharmacokinetics and pharmacodynamics of meperidine after intramuscular and subcutaneous administration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33242227/),[ng] / [ml],265.7,106854,DB00454,Pethidine
,33242227,time to maximal concentration,"Meperidine terminal half-life (T1/2 ), maximal plasma concentrations, and time to maximal concentration were 186 ± 59 and 164 ± 56 minutes, 265.7 ± 47.2 and 243.1 ± 80.1 ng/mL at 17 ± 6, and 24 ± 13 minutes for IM at subcutaneous administration, respectively.",Pharmacokinetics and pharmacodynamics of meperidine after intramuscular and subcutaneous administration in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33242227/),[ng] / [ml],243.1,106855,DB00454,Pethidine
,23719316,total run time,"Chromatographic separation was performed on a C18 column (150 × 2.1 mm internal diameter, 5 μm) using a mobile phase consisting of acetonitrile/water (5 mM ammonium acetate in water, pH 6.2, 40:60, v/v) during a total run time of 4.0 min.",Simultaneous determination of pethidine and norpethidine in mouse plasma by liquid chromatography-electrospray ionization source-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719316/),min,4.0,107527,DB00454,Pethidine
,6835891,half-life,Meptazinol has a half-life of 3.4 hours compared with 22.7 hours for pethidine.,Preliminary clinical and pharmacokinetic experiences in the newborn when meptazinol is compared with pethidine as an obstetric analgesic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6835891/),h,3.4,111437,DB00454,Pethidine
,6835891,half-life,Meptazinol has a half-life of 3.4 hours compared with 22.7 hours for pethidine.,Preliminary clinical and pharmacokinetic experiences in the newborn when meptazinol is compared with pethidine as an obstetric analgesic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6835891/),h,22.7,111438,DB00454,Pethidine
,6835891,PaO2,"Although the mean PaO2 was similar for meptazinol and pethidine, significant variations in the PaO2 of 2.0 kPa or greater and significant neonatal activity as judged by episodes of crying and movement, were recorded in the meptazinol group.",Preliminary clinical and pharmacokinetic experiences in the newborn when meptazinol is compared with pethidine as an obstetric analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6835891/),kpa,2.0,111439,DB00454,Pethidine
,8997460,maximum concentrations,"Substantial interpatient variability in pharmacokinetic parameters was noted for both sites (range of maximum concentrations: 191-500 ng/mL gluteal, 166-374 ng/mL deltoid).",Site-specific pharmacokinetics and pharmacodynamics of intramuscular meperidine in elderly postoperative patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8997460/),[ng] / [ml],191-500,111686,DB00454,Pethidine
,8997460,maximum concentrations,"Substantial interpatient variability in pharmacokinetic parameters was noted for both sites (range of maximum concentrations: 191-500 ng/mL gluteal, 166-374 ng/mL deltoid).",Site-specific pharmacokinetics and pharmacodynamics of intramuscular meperidine in elderly postoperative patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8997460/),[ng] / [ml],166-374,111687,DB00454,Pethidine
,3203014,plasma half-life,The mean plasma half-life of ketobemidone was 2.74 h +/- 0.90 (SD) and the mean relative bioavailability of the mixture was slightly above 100%.,Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203014/),h,2.74,112048,DB00454,Pethidine
above,3203014,relative bioavailability,The mean plasma half-life of ketobemidone was 2.74 h +/- 0.90 (SD) and the mean relative bioavailability of the mixture was slightly above 100%.,Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203014/),%,100,112049,DB00454,Pethidine
,6124079,plasma half-life,"Ketobemidone disappeared rapidly from plasma after i.v. or oral administration, yielding a mean plasma half-life between 2.25 and 2.45 h.",Single-dose kinetics and bioavailability of ketobemidone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124079/),h,2.25 and 2.45,112155,DB00454,Pethidine
,6124079,plasma half-life,"After rectal administration the plasma half-life was somewhat prolonged (3.27 h), probably due to late absorption., The bioavailability of oral ketobemidone was 34% +/- 16% s.d. (n = 6), and when given rectally 44% +/- 9% s.d. (n = 5).",Single-dose kinetics and bioavailability of ketobemidone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124079/),h,3.27,112156,DB00454,Pethidine
,6124079,bioavailability,"After rectal administration the plasma half-life was somewhat prolonged (3.27 h), probably due to late absorption., The bioavailability of oral ketobemidone was 34% +/- 16% s.d. (n = 6), and when given rectally 44% +/- 9% s.d. (n = 5).",Single-dose kinetics and bioavailability of ketobemidone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124079/),%,34,112157,DB00454,Pethidine
,6124079,bioavailability,"After rectal administration the plasma half-life was somewhat prolonged (3.27 h), probably due to late absorption., The bioavailability of oral ketobemidone was 34% +/- 16% s.d. (n = 6), and when given rectally 44% +/- 9% s.d. (n = 5).",Single-dose kinetics and bioavailability of ketobemidone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124079/),%,44,112158,DB00454,Pethidine
,2223366,extraction ratios,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),,0.98,114624,DB00454,Pethidine
,2223366,extraction ratios,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),,0.20,114625,DB00454,Pethidine
,2223366,extraction ratios,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),,0.44,114626,DB00454,Pethidine
,2223366,net fluxes,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[%·dose] / [min],47,114627,DB00454,Pethidine
,2223366,net fluxes,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[%·dose] / [min],5,114628,DB00454,Pethidine
,2223366,net fluxes,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[%·dose] / [min],20,114629,DB00454,Pethidine
,2223366,clearances,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[l] / [min],1.44,114630,DB00454,Pethidine
,2223366,clearances,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[l] / [min],0.17,114631,DB00454,Pethidine
,2223366,clearances,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[l] / [min],0.80,114632,DB00454,Pethidine
,2223366,renal extraction ratio,"During propofol anaesthesia, arterial blood concentrations of pethidine approximately doubled (P less than 0.05), mean pethidine hepatic extraction ratio was unchanged, flux was increased to 145 (20)% and clearance decreased to 79 (10)% (P less than 0.05) of baseline values; mean pethidine renal extraction ratio, flux and clearance were 73 (34), 112 (43) and 69 (31)% of baseline values; mean hindquarter pethidine extraction ratio decreased to 65 (25)% (P less than 0.05) of baseline values.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),,73,114633,DB00454,Pethidine
,434438,steady-state concentration,The mean steady-state concentration of 0.67 microgram/ml was reached by twenty-four hours.,A pharmacokinetic approach to postoperative pain: continuous infusion of pethidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/434438/),[μg] / [ml],0.67,116659,DB00454,Pethidine
,8827580,highest observed concentration,"The highest observed concentration of ketobemidone in breast milk was 36 ng/ml three hours after administration, and 4-7 hours after administration the concentration was 3-5 fold that in maternal plasma.",Excretion of ketobemidone in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827580/),[ng] / [ml],36,116974,DB00454,Pethidine
,7213505,blood clearance,2 The blood clearance of pethidine (mean +/- 2.d.) measured directly was 599 +/- 135 ml/min and is in marked contrast to some reported values.,Pethidine clearance during continuous intravenous infusions in postoperative patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7213505/),[ml] / [min],599,117937,DB00454,Pethidine
,38072,half-lives,"The calculated half-lives were 6.0, 18.5, and 64.5 min.",Pharmacokinetics and analgesic effect of pethidine (meperidine) and its metabolites in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38072/),min,6.0,122773,DB00454,Pethidine
,38072,half-lives,"The calculated half-lives were 6.0, 18.5, and 64.5 min.",Pharmacokinetics and analgesic effect of pethidine (meperidine) and its metabolites in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38072/),min,18.5,122774,DB00454,Pethidine
,38072,half-lives,"The calculated half-lives were 6.0, 18.5, and 64.5 min.",Pharmacokinetics and analgesic effect of pethidine (meperidine) and its metabolites in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38072/),min,64.5,122775,DB00454,Pethidine
,38072,half-lives,"Norpethidine, metabolically formed from pethidine, reached maximum plasma concentrations after 30 min and declined biexponentially with half-lives of 66.8 and 301 min.",Pharmacokinetics and analgesic effect of pethidine (meperidine) and its metabolites in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38072/),min,66.8,122776,DB00454,Pethidine
,38072,half-lives,"Norpethidine, metabolically formed from pethidine, reached maximum plasma concentrations after 30 min and declined biexponentially with half-lives of 66.8 and 301 min.",Pharmacokinetics and analgesic effect of pethidine (meperidine) and its metabolites in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38072/),min,301,122777,DB00454,Pethidine
,19034110,total body clearance rate,"The propofol mean total body clearance rate was 2.09 +/- 0.65 l/min (mean +/- SD), the volume of distribution at steady state was 159 +/- 57 l, and the elimination half-life was 116 +/- 34 min.",Propofol: its role in changing the practice of anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[l] / [min],2.09,124239,DB00454,Pethidine
,19034110,volume of distribution at steady state,"The propofol mean total body clearance rate was 2.09 +/- 0.65 l/min (mean +/- SD), the volume of distribution at steady state was 159 +/- 57 l, and the elimination half-life was 116 +/- 34 min.",Propofol: its role in changing the practice of anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),l,159,124240,DB00454,Pethidine
,19034110,elimination half-life,"The propofol mean total body clearance rate was 2.09 +/- 0.65 l/min (mean +/- SD), the volume of distribution at steady state was 159 +/- 57 l, and the elimination half-life was 116 +/- 34 min.",Propofol: its role in changing the practice of anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),min,116,124241,DB00454,Pethidine
,19034110,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 ml x kg x min ) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Propofol: its role in changing the practice of anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[l] / [min],1.58,124242,DB00454,Pethidine
,19034110,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 ml x kg x min ) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Propofol: its role in changing the practice of anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[l] / [min],2.19,124243,DB00454,Pethidine
,19034110,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 ml x kg x min ) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Propofol: its role in changing the practice of anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),kg·min·ml,33,124244,DB00454,Pethidine
,19034110,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 ml x kg x min ) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Propofol: its role in changing the practice of anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),kg·min·ml,26,124245,DB00454,Pethidine
,19034110,volumes of distribution,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 ml x kg x min ) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Propofol: its role in changing the practice of anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[l] / [kg],2.50,124246,DB00454,Pethidine
,19034110,volumes of distribution,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 ml x kg x min ) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Propofol: its role in changing the practice of anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[l] / [kg],2.05,124247,DB00454,Pethidine
,19034110,elimination half-life,Patients undergoing major (intraabdominal) surgery had longer elimination half-life values (136 +/- 40 vs. 108 +/- 29 min).,Propofol: its role in changing the practice of anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),min,136,124248,DB00454,Pethidine
,19034110,elimination half-life,Patients undergoing major (intraabdominal) surgery had longer elimination half-life values (136 +/- 40 vs. 108 +/- 29 min).,Propofol: its role in changing the practice of anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),min,108,124249,DB00454,Pethidine
,19034110,EC50),"Blood propofol concentrations at which 50% of patients (EC50) were awake and oriented after surgery were 1.07 and 0.95 microgram/ml, respectively.",Propofol: its role in changing the practice of anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[μg] / [ml],1.07,124250,DB00454,Pethidine
,19034110,EC50),"Blood propofol concentrations at which 50% of patients (EC50) were awake and oriented after surgery were 1.07 and 0.95 microgram/ml, respectively.",Propofol: its role in changing the practice of anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[μg] / [ml],0.95,124251,DB00454,Pethidine
,22834454,clearance,"The median (range) values for ketobemidone clearance, apparent volume of distribution, volume of central compartment, distribution half-life and elimination half-life were 0.46 (0.23-0.84) l/h/kg, 4.64 (3.50-7.31) l/kg, 1.71 (0.16-3.47) l/kg, 2.85 (1.04-10.78) min and 7.26 (3.5-11.3) h.",Pharmacokinetics after a single intravenous dose of the opioid ketobemidone in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22834454/),[l] / [h·kg],0.46,135430,DB00454,Pethidine
,22834454,elimination half-life,"The median (range) values for ketobemidone clearance, apparent volume of distribution, volume of central compartment, distribution half-life and elimination half-life were 0.46 (0.23-0.84) l/h/kg, 4.64 (3.50-7.31) l/kg, 1.71 (0.16-3.47) l/kg, 2.85 (1.04-10.78) min and 7.26 (3.5-11.3) h.",Pharmacokinetics after a single intravenous dose of the opioid ketobemidone in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22834454/),h,7.26,135431,DB00454,Pethidine
,3261954,total body clearance rate,"The propofol mean total body clearance rate was 2.09 +/- 0.65 1/min (mean +/- SD), the volume of distribution at steady state was 159 +/- 57 l, and the elimination half-life was 116 +/- 34 min.",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[1] / [min],2.09,139207,DB00454,Pethidine
,3261954,volume of distribution at steady state,"The propofol mean total body clearance rate was 2.09 +/- 0.65 1/min (mean +/- SD), the volume of distribution at steady state was 159 +/- 57 l, and the elimination half-life was 116 +/- 34 min.",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),l,159,139208,DB00454,Pethidine
,3261954,elimination half-life,"The propofol mean total body clearance rate was 2.09 +/- 0.65 1/min (mean +/- SD), the volume of distribution at steady state was 159 +/- 57 l, and the elimination half-life was 116 +/- 34 min.",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),min,116,139209,DB00454,Pethidine
,3261954,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 l.kg-1.min-1) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[l] / [min],1.58,139210,DB00454,Pethidine
,3261954,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 l.kg-1.min-1) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[l] / [min],2.19,139211,DB00454,Pethidine
,3261954,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 l.kg-1.min-1) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[l] / [kg·min],33,139212,DB00454,Pethidine
,3261954,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 l.kg-1.min-1) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[l] / [kg·min],26,139213,DB00454,Pethidine
,3261954,volumes of distribution,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 l.kg-1.min-1) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[l] / [kg],2.50,139214,DB00454,Pethidine
,3261954,volumes of distribution,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 l.kg-1.min-1) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[l] / [kg],2.05,139215,DB00454,Pethidine
,3261954,elimination half-life,Patients undergoing major (intraabdominal) surgery had longer elimination half-life values (136 +/- 40 vs. 108 +/- 29 min).,Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),min,136,139216,DB00454,Pethidine
,3261954,elimination half-life,Patients undergoing major (intraabdominal) surgery had longer elimination half-life values (136 +/- 40 vs. 108 +/- 29 min).,Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),min,108,139217,DB00454,Pethidine
,3261954,EC50),"Blood propofol concentrations at which 50% of patients (EC50) were awake and oriented after surgery were 1.07 and 0.95 microgram/ml, respectively.",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[μg] / [ml],1.07,139218,DB00454,Pethidine
,3261954,EC50),"Blood propofol concentrations at which 50% of patients (EC50) were awake and oriented after surgery were 1.07 and 0.95 microgram/ml, respectively.",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[μg] / [ml],0.95,139219,DB00454,Pethidine
,20407249,elimination half-life,"Remifentanil, due to its pharmacokinetic profile (elimination half-life: 9 min), is advantageous for ambulatory patients, though it is not known whether the high cost compensates the benefits.",Pharmacology of sedation agents and reversal agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20407249/),min,9,139670,DB00454,Pethidine
,9197301,half-lives of equilibrium,"The half-lives of equilibrium between blood and brain were 6.3 and 0.8 min for meperidine and alfentanil, respectively: The rate of penetration of both opioids into the brain was rapid and not rate-limiting.",The cerebral pharmacokinetics of meperidine and alfentanil in conscious sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9197301/),min,6.3,145020,DB00454,Pethidine
,9197301,half-lives of equilibrium,"The half-lives of equilibrium between blood and brain were 6.3 and 0.8 min for meperidine and alfentanil, respectively: The rate of penetration of both opioids into the brain was rapid and not rate-limiting.",The cerebral pharmacokinetics of meperidine and alfentanil in conscious sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9197301/),min,0.8,145021,DB00454,Pethidine
,3441166,elimination half-life,"The elimination half-life after I.V., P.O. and buccal routes was 0.75 +/- 0.14 hours, 0.93 +/- 0.18 hours and 0.36 +/- 0.10 hours, respectively.","Meperidine pharmacokinetics following intravenous, peroral and buccal administration in beagle dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3441166/),h,0.75,147116,DB00454,Pethidine
,3441166,elimination half-life,"The elimination half-life after I.V., P.O. and buccal routes was 0.75 +/- 0.14 hours, 0.93 +/- 0.18 hours and 0.36 +/- 0.10 hours, respectively.","Meperidine pharmacokinetics following intravenous, peroral and buccal administration in beagle dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3441166/),h,0.93,147117,DB00454,Pethidine
,3441166,elimination half-life,"The elimination half-life after I.V., P.O. and buccal routes was 0.75 +/- 0.14 hours, 0.93 +/- 0.18 hours and 0.36 +/- 0.10 hours, respectively.","Meperidine pharmacokinetics following intravenous, peroral and buccal administration in beagle dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3441166/),h,0.36,147118,DB00454,Pethidine
,3441166,volume of distribution,"The volume of distribution and total clearance following I.V., P.O. and buccal administration were 2.41 +/- 0.34 L/kg and 42.5 +/- 8.9 ml/min/kg, 2.84 +/- 1.24 L/kg and 34.6 +/- 7.8 ml/min/kg, 1.01 +/- 0.52 L/kg and 34.7 +/- 8.0 ml/min/kg, respectively.","Meperidine pharmacokinetics following intravenous, peroral and buccal administration in beagle dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3441166/),[l] / [kg],2.41,147119,DB00454,Pethidine
,3441166,volume of distribution,"The volume of distribution and total clearance following I.V., P.O. and buccal administration were 2.41 +/- 0.34 L/kg and 42.5 +/- 8.9 ml/min/kg, 2.84 +/- 1.24 L/kg and 34.6 +/- 7.8 ml/min/kg, 1.01 +/- 0.52 L/kg and 34.7 +/- 8.0 ml/min/kg, respectively.","Meperidine pharmacokinetics following intravenous, peroral and buccal administration in beagle dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3441166/),[l] / [kg],2.84,147120,DB00454,Pethidine
,3441166,total clearance,"The volume of distribution and total clearance following I.V., P.O. and buccal administration were 2.41 +/- 0.34 L/kg and 42.5 +/- 8.9 ml/min/kg, 2.84 +/- 1.24 L/kg and 34.6 +/- 7.8 ml/min/kg, 1.01 +/- 0.52 L/kg and 34.7 +/- 8.0 ml/min/kg, respectively.","Meperidine pharmacokinetics following intravenous, peroral and buccal administration in beagle dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3441166/),[ml] / [kg·min],34.7,147121,DB00454,Pethidine
,3441166,absolute bioavailability,"The absolute bioavailability after P.O. and buccal administration was 11.0 +/- 6.8% and 11.9 +/- 6.6%, respectively.","Meperidine pharmacokinetics following intravenous, peroral and buccal administration in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3441166/),%,11.0,147122,DB00454,Pethidine
,3441166,absolute bioavailability,"The absolute bioavailability after P.O. and buccal administration was 11.0 +/- 6.8% and 11.9 +/- 6.6%, respectively.","Meperidine pharmacokinetics following intravenous, peroral and buccal administration in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3441166/),%,11.9,147123,DB00454,Pethidine
,2051311,time-averaged extraction ratios,"The mean and SD (n = 4) of the time-averaged extraction ratios across the hindquarters (determined from the relevant arterio-venous area under blood concentration--time curves) were 0.12 (0.10), 0.36 (0.13), and 0.27 (0.05) for chlormethiazole, meperidine, and minaxolone, respectively.","Uptake and elution of chlormethiazole, meperidine, and minaxolone in the hindquarters of sheep: implications for clearance calculations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051311/),,0.12,149925,DB00454,Pethidine
,2051311,time-averaged extraction ratios,"The mean and SD (n = 4) of the time-averaged extraction ratios across the hindquarters (determined from the relevant arterio-venous area under blood concentration--time curves) were 0.12 (0.10), 0.36 (0.13), and 0.27 (0.05) for chlormethiazole, meperidine, and minaxolone, respectively.","Uptake and elution of chlormethiazole, meperidine, and minaxolone in the hindquarters of sheep: implications for clearance calculations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051311/),,0.36,149926,DB00454,Pethidine
,2051311,time-averaged extraction ratios,"The mean and SD (n = 4) of the time-averaged extraction ratios across the hindquarters (determined from the relevant arterio-venous area under blood concentration--time curves) were 0.12 (0.10), 0.36 (0.13), and 0.27 (0.05) for chlormethiazole, meperidine, and minaxolone, respectively.","Uptake and elution of chlormethiazole, meperidine, and minaxolone in the hindquarters of sheep: implications for clearance calculations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051311/),,0.27,149927,DB00454,Pethidine
,6102913,oral bioavailability,"The average oral bioavailability of ketobemiodone was 34% +/- 16% (SD, n = 6).",Clinical pharmacokinetics and oral bioavailability of ketobemidone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6102913/),%,34,152561,DB00454,Pethidine
,6102913,plasma half-life of elimination (t1/2 beta),"The mean plasma half-life of elimination (t1/2 beta) was about the same following oral (2.45 +/- 0.73 h; SD, n = 5) as after intravenous administration (2.25 +/- 0.35 h; SD, n = 6).",Clinical pharmacokinetics and oral bioavailability of ketobemidone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6102913/),h,2.45,152562,DB00454,Pethidine
,6102913,plasma half-life of elimination (t1/2 beta),"The mean plasma half-life of elimination (t1/2 beta) was about the same following oral (2.45 +/- 0.73 h; SD, n = 5) as after intravenous administration (2.25 +/- 0.35 h; SD, n = 6).",Clinical pharmacokinetics and oral bioavailability of ketobemidone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6102913/),h,2.25,152563,DB00454,Pethidine
,2635070,fraction bound to plasma proteins,"The fraction bound to plasma proteins was 45% in man, 29% in rats, and 27% in rabbits.",[Distribution of 14C-pethidine in the blood of certain species]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2635070/),%,45,158262,DB00454,Pethidine
,2635070,fraction bound to plasma proteins,"The fraction bound to plasma proteins was 45% in man, 29% in rats, and 27% in rabbits.",[Distribution of 14C-pethidine in the blood of certain species]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2635070/),%,29,158263,DB00454,Pethidine
,2635070,fraction bound to plasma proteins,"The fraction bound to plasma proteins was 45% in man, 29% in rats, and 27% in rabbits.",[Distribution of 14C-pethidine in the blood of certain species]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2635070/),%,27,158264,DB00454,Pethidine
,2635070,portion of the free fraction,"The portion of the free fraction was 22% in man, 27% in rats, and 19% in rabbits.",[Distribution of 14C-pethidine in the blood of certain species]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2635070/),%,22,158265,DB00454,Pethidine
,2635070,portion of the free fraction,"The portion of the free fraction was 22% in man, 27% in rats, and 19% in rabbits.",[Distribution of 14C-pethidine in the blood of certain species]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2635070/),%,27,158266,DB00454,Pethidine
,2635070,portion of the free fraction,"The portion of the free fraction was 22% in man, 27% in rats, and 19% in rabbits.",[Distribution of 14C-pethidine in the blood of certain species]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2635070/),%,19,158267,DB00454,Pethidine
,7192957,half-life,"Our findings agree with those reported in the literature following a total dose of 50 mg (half-life average 4.4 hours, total plasma clearance 10.4 ml/min/kg, and apparent volume of distribution 3.74 L/kg).",Pharmacokinetics of high-dose meperidine in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7192957/),h,4.4,158968,DB00454,Pethidine
,7192957,total plasma clearance,"Our findings agree with those reported in the literature following a total dose of 50 mg (half-life average 4.4 hours, total plasma clearance 10.4 ml/min/kg, and apparent volume of distribution 3.74 L/kg).",Pharmacokinetics of high-dose meperidine in surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7192957/),[ml] / [kg·min],10.4,158969,DB00454,Pethidine
,7192957,apparent volume of distribution,"Our findings agree with those reported in the literature following a total dose of 50 mg (half-life average 4.4 hours, total plasma clearance 10.4 ml/min/kg, and apparent volume of distribution 3.74 L/kg).",Pharmacokinetics of high-dose meperidine in surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7192957/),[l] / [kg],3.74,158970,DB00454,Pethidine
,3578943,peak plasma concentration,The peak plasma concentration of pethidine was 176 +/- 66 ng X ml-1 (range: 84-208) and the time to peak concentration was 2.3 +/- 1.4 h (range: 0.5-6 h).,[Pharmacokinetics of pethidine after spinal anesthesia. Clinical implications]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578943/),[ng] / [ml],176,168633,DB00454,Pethidine
,3578943,time to peak concentration,The peak plasma concentration of pethidine was 176 +/- 66 ng X ml-1 (range: 84-208) and the time to peak concentration was 2.3 +/- 1.4 h (range: 0.5-6 h).,[Pharmacokinetics of pethidine after spinal anesthesia. Clinical implications]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578943/),h,2.3,168634,DB00454,Pethidine
,3578943,terminal elimination half-life,The terminal elimination half-life was 7.2 +/- 2.2 h (range: 4-11.5 h).,[Pharmacokinetics of pethidine after spinal anesthesia. Clinical implications]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578943/),h,7.2,168635,DB00454,Pethidine
>,11408525,K(i)delta/K(i)mu),"H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA) were found to display high binding affinity and much greater selectivity for the mu-opioid receptor (K(i)delta/K(i)mu) > 10,000) compared with H-Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO).",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),,"10,000",169074,DB00454,Pethidine
,11408525,apparent volume of distribution,"When given intravenously to sheep, the apparent volume of distribution was 50 to 80 ml/kg for all three peptides, suggesting that distribution was limited to blood volume.",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),[ml] / [kg],50 to 80,169075,DB00454,Pethidine
,11408525,Plasma clearance,"Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively.",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),[ml] / [h·kg],223,169076,DB00454,Pethidine
,11408525,Plasma clearance,"Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively.",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),[ml] / [h·kg],24,169077,DB00454,Pethidine
,11408525,elimination half-lives,"Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively.",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),h,0.24,169078,DB00454,Pethidine
,11408525,elimination half-lives,"Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively.",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),h,1.5,169079,DB00454,Pethidine
,11408525,elimination half-lives,"Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively.",In vivo pharmacokinetics of selective mu-opioid peptide agonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408525/),h,1.8,169080,DB00454,Pethidine
,8908225,volume of distribution at steady state,"The volume of distribution at steady state was 4.7 (0.7)l/kg, systemic plasma clearance was 7.8 (1.5) (mean (SD)) ml/kg/min.",Pharmacokinetics of piritramide after an intravenous bolus in surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8908225/),[l] / [kg],4.7,169806,DB00454,Pethidine
,8908225,systemic plasma clearance,"The volume of distribution at steady state was 4.7 (0.7)l/kg, systemic plasma clearance was 7.8 (1.5) (mean (SD)) ml/kg/min.",Pharmacokinetics of piritramide after an intravenous bolus in surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8908225/),[ml] / [kg·min],7.8,169807,DB00454,Pethidine
,8908225,Renal clearance,Renal clearance of unchanged piritramide was negligible (0.13 (0.09) ml/kg/min).,Pharmacokinetics of piritramide after an intravenous bolus in surgical patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8908225/),[ml] / [kg·min],0.13,169808,DB00454,Pethidine
,8908225,terminal elimination half-life,The terminal elimination half-life was 8.0 (1.4) h.,Pharmacokinetics of piritramide after an intravenous bolus in surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8908225/),h,8.0,169809,DB00454,Pethidine
,2568289,Half-lives,"Half-lives of the rapid and terminal elimination phases were calculated as 2.3 and 13.3 h, respectively.",Pharmacokinetics of meperidine in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568289/),h,2.3,172936,DB00454,Pethidine
,2568289,Half-lives,"Half-lives of the rapid and terminal elimination phases were calculated as 2.3 and 13.3 h, respectively.",Pharmacokinetics of meperidine in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568289/),h,13.3,172937,DB00454,Pethidine
,6589939,duration of analgesia,"The mean duration of analgesia after E.D. administration was dose-related (8.6 +/- 2.0 h, 13.0 +/- 3.5 h, and 15.6 +/- 2.6 h; means +/- SEM for the 2, 4 and 6 mg groups, respectively), which was comparable to that achieved after I.T. administration of 0.25 to 0.50 mg M. M. concentrations in plasma after E.D. administration were comparable in variability and magnitude to those found after I.M. administration.",Pharmacokinetic aspects of spinal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589939/),h,8.6,183621,DB00454,Pethidine
,6589939,duration of analgesia,"The mean duration of analgesia after E.D. administration was dose-related (8.6 +/- 2.0 h, 13.0 +/- 3.5 h, and 15.6 +/- 2.6 h; means +/- SEM for the 2, 4 and 6 mg groups, respectively), which was comparable to that achieved after I.T. administration of 0.25 to 0.50 mg M. M. concentrations in plasma after E.D. administration were comparable in variability and magnitude to those found after I.M. administration.",Pharmacokinetic aspects of spinal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589939/),h,13.0,183622,DB00454,Pethidine
,6589939,duration of analgesia,"The mean duration of analgesia after E.D. administration was dose-related (8.6 +/- 2.0 h, 13.0 +/- 3.5 h, and 15.6 +/- 2.6 h; means +/- SEM for the 2, 4 and 6 mg groups, respectively), which was comparable to that achieved after I.T. administration of 0.25 to 0.50 mg M. M. concentrations in plasma after E.D. administration were comparable in variability and magnitude to those found after I.M. administration.",Pharmacokinetic aspects of spinal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589939/),h,15.6,183623,DB00454,Pethidine
,6589939,CSF/plasma concentration ratio,This is to be compared with a CSF/plasma concentration ratio around 100 after E.D. administration.,Pharmacokinetic aspects of spinal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589939/),,100,183624,DB00454,Pethidine
,3063133,respiratory rate,"Ventilation was performed mechanically during the entire operative period (N2O/O2 - FiO2:0.33, tidal volume 10 ml/kg, respiratory rate: 14/min).",[Response of human growth hormone to anesthesia induction with propofol]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063133/),1/[min],14,187266,DB00454,Pethidine
,7122111,bioavailability,"In the third patient, whose eneral bioavailability was only 20%, the MEAC was not obtained.",Clinical pharmacokinetics applied to patients with intractable pain: studies with pethidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7122111/),%,20,189940,DB00454,Pethidine
,3987796,cumulative urinary excretion,"The cumulative urinary excretion of norpethidine and norpethidinic acid during 24 h was significantly lower in old patients than in young: 2.7% versus 7.1% (p less than 0.001), and 5.5% versus 10.5% (p less than 0.001).",Comparison of renal excretion of pethidine (meperidine) and its metabolites in old and young patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987796/),%,2.7,190790,DB00454,Pethidine
,3987796,cumulative urinary excretion,"The cumulative urinary excretion of norpethidine and norpethidinic acid during 24 h was significantly lower in old patients than in young: 2.7% versus 7.1% (p less than 0.001), and 5.5% versus 10.5% (p less than 0.001).",Comparison of renal excretion of pethidine (meperidine) and its metabolites in old and young patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987796/),%,7.1,190791,DB00454,Pethidine
,3987796,cumulative urinary excretion,"The cumulative urinary excretion of norpethidine and norpethidinic acid during 24 h was significantly lower in old patients than in young: 2.7% versus 7.1% (p less than 0.001), and 5.5% versus 10.5% (p less than 0.001).",Comparison of renal excretion of pethidine (meperidine) and its metabolites in old and young patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987796/),%,5.5,190792,DB00454,Pethidine
,3987796,cumulative urinary excretion,"The cumulative urinary excretion of norpethidine and norpethidinic acid during 24 h was significantly lower in old patients than in young: 2.7% versus 7.1% (p less than 0.001), and 5.5% versus 10.5% (p less than 0.001).",Comparison of renal excretion of pethidine (meperidine) and its metabolites in old and young patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987796/),%,10.5,190793,DB00454,Pethidine
,6937164,bioavailability,"In the presence of liver disease, the bioavailability of pethidine was 31% and pentazocine 233% greater than in normals.",Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6937164/),%,31,191181,DB00454,Pethidine
,6937164,bioavailability,"In the presence of liver disease, the bioavailability of pethidine was 31% and pentazocine 233% greater than in normals.",Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6937164/),%,233,191182,DB00454,Pethidine
,1467165,duration of severe pain,"However, the duration of severe pain was significantly shorter in phase B (0.9 +/- 1.0 days) than in phase A (2.0 +/- 1.8 days).",Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467165/),d,0.9,198696,DB00454,Pethidine
,1467165,duration of severe pain,"However, the duration of severe pain was significantly shorter in phase B (0.9 +/- 1.0 days) than in phase A (2.0 +/- 1.8 days).",Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467165/),d,2.0,198697,DB00454,Pethidine
,1467165,Total body clearance (TBC),Total body clearance (TBC) of morphine was greater in children before puberty than after (40.4 +/- 10 vs. 28 +/- 11 mL/kg/min; p < 0.05).,Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467165/),[ml] / [kg·min],40.4,198698,DB00454,Pethidine
,1467165,Total body clearance (TBC),Total body clearance (TBC) of morphine was greater in children before puberty than after (40.4 +/- 10 vs. 28 +/- 11 mL/kg/min; p < 0.05).,Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467165/),[ml] / [kg·min],28,198699,DB00454,Pethidine
,3965235,Systemic clearance,"Systemic clearance (8.61 +/- 2.22 ml/min/kg), apparent oral clearance (17.5 +/- 5.5 ml/min/kg), terminal t1/2 (6.98 +/- 1.86 hr), and the blood/plasma concentration ratio (0.97 +/- 0.12) in the elderly did not differ from those in younger subjects.",Effects of age on meperidine disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965235/),[ml] / [kg·min],8.61,199178,DB00454,Pethidine
,3965235,apparent oral clearance,"Systemic clearance (8.61 +/- 2.22 ml/min/kg), apparent oral clearance (17.5 +/- 5.5 ml/min/kg), terminal t1/2 (6.98 +/- 1.86 hr), and the blood/plasma concentration ratio (0.97 +/- 0.12) in the elderly did not differ from those in younger subjects.",Effects of age on meperidine disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965235/),[ml] / [kg·min],17.5,199179,DB00454,Pethidine
,3965235,terminal t1/2,"Systemic clearance (8.61 +/- 2.22 ml/min/kg), apparent oral clearance (17.5 +/- 5.5 ml/min/kg), terminal t1/2 (6.98 +/- 1.86 hr), and the blood/plasma concentration ratio (0.97 +/- 0.12) in the elderly did not differ from those in younger subjects.",Effects of age on meperidine disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965235/),h,6.98,199180,DB00454,Pethidine
,3965235,blood/plasma concentration ratio,"Systemic clearance (8.61 +/- 2.22 ml/min/kg), apparent oral clearance (17.5 +/- 5.5 ml/min/kg), terminal t1/2 (6.98 +/- 1.86 hr), and the blood/plasma concentration ratio (0.97 +/- 0.12) in the elderly did not differ from those in younger subjects.",Effects of age on meperidine disposition. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965235/),,0.97,199181,DB00454,Pethidine
,3965235,initial,"In the elderly, however, the initial (2.4 +/- 0.8 l/kg) and the steady-state (4.6 +/- 0.9 l/kg) volumes of distribution were 300% and 135% values in the young.",Effects of age on meperidine disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965235/),[l] / [kg],2.4,199182,DB00454,Pethidine
,3965235,steady-state,"In the elderly, however, the initial (2.4 +/- 0.8 l/kg) and the steady-state (4.6 +/- 0.9 l/kg) volumes of distribution were 300% and 135% values in the young.",Effects of age on meperidine disposition. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965235/),[l] / [kg],4.6,199183,DB00454,Pethidine
,3965235,volumes of distribution,"In the elderly, however, the initial (2.4 +/- 0.8 l/kg) and the steady-state (4.6 +/- 0.9 l/kg) volumes of distribution were 300% and 135% values in the young.",Effects of age on meperidine disposition. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965235/),[l] / [kg],4.6,199184,DB00454,Pethidine
,3965235,volumes of distribution,"In the elderly, however, the initial (2.4 +/- 0.8 l/kg) and the steady-state (4.6 +/- 0.9 l/kg) volumes of distribution were 300% and 135% values in the young.",Effects of age on meperidine disposition. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965235/),%,135,199185,DB00454,Pethidine
,532541,plasma concentration,The mean measured plasma concentration of pethidine which provided adequate analgesia was 738 +/- 149 ng/ml.,Patient controlled analgesic therapy in the early postoperative period. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/532541/),[ng] / [ml],738,203767,DB00454,Pethidine
,4020636,Pulmonary clearance,"Pulmonary clearance, calculated from concentration differences between pulmonary arterial and left ventricular blood and pulmonary blood flow, averaged 12.1 +/- 3.70 mL/min/kg, accounting for 58 +/- 13% of the total clearance of the drug.",Contribution of the lung to total body clearance of meperidine in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020636/),[ml] / [kg·min],12.1,208603,DB00454,Pethidine
,3573868,"terminal half-lives, t 1/2","There was no significant difference in the terminal half-lives, t 1/2 (6.1 to 7.0 hr) of pethidine, although the area under the plasma concentration-time curve under acidic urinary conditions was slightly lower and renal clearance of the drug higher than those under alkaline and uncontrolled urinary conditions.",Influence of urinary pH on pethidine kinetics in healthy volunteer subjects. 2. A study of ten Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3573868/),h,6.1 to 7.0,214160,DB00454,Pethidine
,7365693,constant rate,"Meperidine was infused at a constant rate of 3.2 mg/min into the maternal vena cava, and [14C]inulin was infused at a constant rate of 0.22 muCi/min into the fetal vena cava.",Renal tubular secretion of meperidine by the fetal lamb. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365693/),,0.22,217026,DB00454,Pethidine
,7365693,clearance,"The mean meperidine clearance in 12 studies was 12.04 +/- 2.90 (S.E.) ml/min, whereas mean inulin clearance was 2.48 +/- 0.35 (S.E.) ml/min.",Renal tubular secretion of meperidine by the fetal lamb. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365693/),[ml] / [min],12.04,217027,DB00454,Pethidine
,7365693,inulin clearance,"The mean meperidine clearance in 12 studies was 12.04 +/- 2.90 (S.E.) ml/min, whereas mean inulin clearance was 2.48 +/- 0.35 (S.E.) ml/min.",Renal tubular secretion of meperidine by the fetal lamb. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365693/),[ml] / [min],2.48,217028,DB00454,Pethidine
,7358866,Plasma clearances,Plasma clearances for the two narcotics are nearly identical (1.04 l./kg/min for alphaprodine and 1.01 l./kg/min for meperidine).,A comparison of alphaprodine and meperidine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7358866/),[l] / [kg·min],1.04,217386,DB00454,Pethidine
,7358866,Plasma clearances,Plasma clearances for the two narcotics are nearly identical (1.04 l./kg/min for alphaprodine and 1.01 l./kg/min for meperidine).,A comparison of alphaprodine and meperidine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7358866/),[l] / [kg·min],1.01,217387,DB00454,Pethidine
,7358866,apparent volume of distribution,The apparent volume of distribution for alphaprodine is smaller than for meperidine (1.90 l./kg for alphaprodine and 3.37 l./kg for meperidine).,A comparison of alphaprodine and meperidine pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7358866/),[l] / [kg],1.90,217388,DB00454,Pethidine
,7358866,apparent volume of distribution,The apparent volume of distribution for alphaprodine is smaller than for meperidine (1.90 l./kg for alphaprodine and 3.37 l./kg for meperidine).,A comparison of alphaprodine and meperidine pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7358866/),[l] / [kg],3.37,217389,DB00454,Pethidine
,6953729,terminal elimination half-lives,The terminal elimination half-lives of pethidine in plasma are 5-7 h for all routes of administration.,Regional epidural analgesia: kinetics of pethidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953729/),h,5-7,218553,DB00454,Pethidine
,1389817,plasma half-lives,"Maternal plasma half-lives for pethidine and bupivacaine were 1.0 and 2.0 h, and placental half-lives 1.9 and 2.5 h, respectively.",Elimination of bupivacaine and pethidine from the rabbit feto-placental unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389817/),h,1.0,219011,DB00454,Pethidine
,1389817,plasma half-lives,"Maternal plasma half-lives for pethidine and bupivacaine were 1.0 and 2.0 h, and placental half-lives 1.9 and 2.5 h, respectively.",Elimination of bupivacaine and pethidine from the rabbit feto-placental unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389817/),h,2.0,219012,DB00454,Pethidine
,1389817,half-lives,"Maternal plasma half-lives for pethidine and bupivacaine were 1.0 and 2.0 h, and placental half-lives 1.9 and 2.5 h, respectively.",Elimination of bupivacaine and pethidine from the rabbit feto-placental unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389817/),h,1.9,219013,DB00454,Pethidine
,1389817,half-lives,"Maternal plasma half-lives for pethidine and bupivacaine were 1.0 and 2.0 h, and placental half-lives 1.9 and 2.5 h, respectively.",Elimination of bupivacaine and pethidine from the rabbit feto-placental unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389817/),h,2.5,219014,DB00454,Pethidine
,1389817,apparent fetal plasma half-life,The apparent fetal plasma half-life of pethidine was 9.9 h while there was apparently no net elimination of bupivacaine from fetal plasma.,Elimination of bupivacaine and pethidine from the rabbit feto-placental unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389817/),h,9.9,219015,DB00454,Pethidine
,4033301,terminal t1/2,"Although large variations in the 48 hr urinary recovery of pethidine and norpethidine (26.9 +/- 5.9% & 23.4 +/- 4.6%, 0.6 +/- 0.3% & 3.6 +/- 1.6%, 6.9 +/- 3.2% & 17.4 +/- 6.6%, respectively, under acidic, alkaline and uncontrolled urinary pH were induced by change in urinary pH, the terminal t1/2 (7-8 hr), the AUC and the plasma concentration-time profiles were not affected.",Influence of urinary pH on pethidine kinetics in healthy volunteer subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4033301/),h,7-8,220492,DB00454,Pethidine
,19839946,clearance,"The values of ketobemidone clearance (l/h/kg) given as median (range) were 0.84 (0.29-3.0) in Group A (0-90 days), 0.89 (0.55-1.35) in Group B (1-2.5 years) and 0.74 (0.50-0.99) in Group C (7-10 years).",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),[l] / [h·kg],0.84,220647,DB00454,Pethidine
,19839946,clearance,"The values of ketobemidone clearance (l/h/kg) given as median (range) were 0.84 (0.29-3.0) in Group A (0-90 days), 0.89 (0.55-1.35) in Group B (1-2.5 years) and 0.74 (0.50-0.99) in Group C (7-10 years).",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),[l] / [h·kg],0.89,220648,DB00454,Pethidine
,19839946,clearance,"The values of ketobemidone clearance (l/h/kg) given as median (range) were 0.84 (0.29-3.0) in Group A (0-90 days), 0.89 (0.55-1.35) in Group B (1-2.5 years) and 0.74 (0.50-0.99) in Group C (7-10 years).",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),[l] / [h·kg],0.74,220649,DB00454,Pethidine
,19839946,apparent volume of distribution,"The corresponding values for apparent volume of distribution (l/kg) were 4.4 (3.7-6.9) (Group A), 2.6 (2.0-5.6) (Group B) and 3.9 (2.7-5.0 (Group C), and for elimination half-life (h) 3.0 (1.4-8.9) (Group A), 2.0 (1.2-4.7) (Group B) and 3.7 (2.4-6.9) (Group C), respectively.",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),[l] / [kg],4.4,220650,DB00454,Pethidine
,19839946,apparent volume of distribution,"The corresponding values for apparent volume of distribution (l/kg) were 4.4 (3.7-6.9) (Group A), 2.6 (2.0-5.6) (Group B) and 3.9 (2.7-5.0 (Group C), and for elimination half-life (h) 3.0 (1.4-8.9) (Group A), 2.0 (1.2-4.7) (Group B) and 3.7 (2.4-6.9) (Group C), respectively.",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),[l] / [kg],2.6,220651,DB00454,Pethidine
,19839946,apparent volume of distribution,"The corresponding values for apparent volume of distribution (l/kg) were 4.4 (3.7-6.9) (Group A), 2.6 (2.0-5.6) (Group B) and 3.9 (2.7-5.0 (Group C), and for elimination half-life (h) 3.0 (1.4-8.9) (Group A), 2.0 (1.2-4.7) (Group B) and 3.7 (2.4-6.9) (Group C), respectively.",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),[l] / [kg],3.9,220652,DB00454,Pethidine
,19839946,elimination half-life,"The corresponding values for apparent volume of distribution (l/kg) were 4.4 (3.7-6.9) (Group A), 2.6 (2.0-5.6) (Group B) and 3.9 (2.7-5.0 (Group C), and for elimination half-life (h) 3.0 (1.4-8.9) (Group A), 2.0 (1.2-4.7) (Group B) and 3.7 (2.4-6.9) (Group C), respectively.",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),h,3.0,220653,DB00454,Pethidine
,19839946,elimination half-life,"The corresponding values for apparent volume of distribution (l/kg) were 4.4 (3.7-6.9) (Group A), 2.6 (2.0-5.6) (Group B) and 3.9 (2.7-5.0 (Group C), and for elimination half-life (h) 3.0 (1.4-8.9) (Group A), 2.0 (1.2-4.7) (Group B) and 3.7 (2.4-6.9) (Group C), respectively.",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),h,2.0,220654,DB00454,Pethidine
,19839946,elimination half-life,"The corresponding values for apparent volume of distribution (l/kg) were 4.4 (3.7-6.9) (Group A), 2.6 (2.0-5.6) (Group B) and 3.9 (2.7-5.0 (Group C), and for elimination half-life (h) 3.0 (1.4-8.9) (Group A), 2.0 (1.2-4.7) (Group B) and 3.7 (2.4-6.9) (Group C), respectively.",Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),h,3.7,220655,DB00454,Pethidine
,19839946,elimination half-life,In the two neonates the elimination half-life was almost 9 h.,Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839946/),h,9,220656,DB00454,Pethidine
,3655004,elimination half-life (t1/2),"The mean +/- SEM elimination half-life (t1/2) of pethidine was significantly longer in the three groups of renal patients: 7.9 +/- 1.1, 20.2 +/- 13.6, 16.6 +/- 5.4, and 14.3 +/- 3.1 hr, respectively, for healthy volunteers, patients with severe, moderate, and mild dysfunction; their mean +/- SEM creatinine clearances were 97.3 +/- 7.5, less than 9.5, 30.0 (3.7), and 63.3 +/- 8.5 mL/min respectively.",Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655004/),h,7.9,221966,DB00454,Pethidine
,3655004,elimination half-life (t1/2),"The mean +/- SEM elimination half-life (t1/2) of pethidine was significantly longer in the three groups of renal patients: 7.9 +/- 1.1, 20.2 +/- 13.6, 16.6 +/- 5.4, and 14.3 +/- 3.1 hr, respectively, for healthy volunteers, patients with severe, moderate, and mild dysfunction; their mean +/- SEM creatinine clearances were 97.3 +/- 7.5, less than 9.5, 30.0 (3.7), and 63.3 +/- 8.5 mL/min respectively.",Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655004/),h,20.2,221967,DB00454,Pethidine
,3655004,elimination half-life (t1/2),"The mean +/- SEM elimination half-life (t1/2) of pethidine was significantly longer in the three groups of renal patients: 7.9 +/- 1.1, 20.2 +/- 13.6, 16.6 +/- 5.4, and 14.3 +/- 3.1 hr, respectively, for healthy volunteers, patients with severe, moderate, and mild dysfunction; their mean +/- SEM creatinine clearances were 97.3 +/- 7.5, less than 9.5, 30.0 (3.7), and 63.3 +/- 8.5 mL/min respectively.",Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655004/),h,16.6,221968,DB00454,Pethidine
,3655004,elimination half-life (t1/2),"The mean +/- SEM elimination half-life (t1/2) of pethidine was significantly longer in the three groups of renal patients: 7.9 +/- 1.1, 20.2 +/- 13.6, 16.6 +/- 5.4, and 14.3 +/- 3.1 hr, respectively, for healthy volunteers, patients with severe, moderate, and mild dysfunction; their mean +/- SEM creatinine clearances were 97.3 +/- 7.5, less than 9.5, 30.0 (3.7), and 63.3 +/- 8.5 mL/min respectively.",Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655004/),h,14.3,221969,DB00454,Pethidine
,3655004,plasma clearance,"The mean plasma clearance of the drug was higher in healthy subjects (342.7 +/- 62.5 mL/min) than various groups of renal patients (99.9 +/- 11.6, 120.9 +/- 45.8, and 123.8 +/- 34.1, respectively, for patients with severe, moderate, and mild dysfunction).",Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655004/),[ml] / [min],342.7,221970,DB00454,Pethidine
,3655004,plasma clearance,"The mean plasma clearance of the drug was higher in healthy subjects (342.7 +/- 62.5 mL/min) than various groups of renal patients (99.9 +/- 11.6, 120.9 +/- 45.8, and 123.8 +/- 34.1, respectively, for patients with severe, moderate, and mild dysfunction).",Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655004/),[ml] / [min],99.9,221971,DB00454,Pethidine
,3655004,plasma clearance,"The mean plasma clearance of the drug was higher in healthy subjects (342.7 +/- 62.5 mL/min) than various groups of renal patients (99.9 +/- 11.6, 120.9 +/- 45.8, and 123.8 +/- 34.1, respectively, for patients with severe, moderate, and mild dysfunction).",Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655004/),[ml] / [min],120.9,221972,DB00454,Pethidine
,3655004,plasma clearance,"The mean plasma clearance of the drug was higher in healthy subjects (342.7 +/- 62.5 mL/min) than various groups of renal patients (99.9 +/- 11.6, 120.9 +/- 45.8, and 123.8 +/- 34.1, respectively, for patients with severe, moderate, and mild dysfunction).",Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3655004/),[ml] / [min],123.8,221973,DB00454,Pethidine
,3356051,peak serum concentration,The absorption of acetaminophen was incomplete (peak serum concentration: 70.8 mumol.L-1) and delayed.,Pharmacokinetics and clinical efficacy of intrarectal solution of acetaminophen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356051/),[μM] / [l],70.8,222615,DB00454,Pethidine
,2314154,Tmax,The Tmax was faster in the Caucasian group (0.75 h) compared with the Chinese group (1.0 h) and the Indian group (1.5 h).,"Disposition of pethidine in man under acidic urinary pH. 4. Kinetics after oral dose in caucasian, Chinese and Indian subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2314154/),h,0.75,222931,DB00454,Pethidine
,2314154,Tmax,The Tmax was faster in the Caucasian group (0.75 h) compared with the Chinese group (1.0 h) and the Indian group (1.5 h).,"Disposition of pethidine in man under acidic urinary pH. 4. Kinetics after oral dose in caucasian, Chinese and Indian subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2314154/),h,1.0,222932,DB00454,Pethidine
,2314154,Tmax,The Tmax was faster in the Caucasian group (0.75 h) compared with the Chinese group (1.0 h) and the Indian group (1.5 h).,"Disposition of pethidine in man under acidic urinary pH. 4. Kinetics after oral dose in caucasian, Chinese and Indian subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2314154/),h,1.5,222933,DB00454,Pethidine
,2314154,absorption t1/2,No significant difference was observed in their respective lag time while the absorption t1/2 was significantly shortest in the Caucasian group who also had the highest Cmax (95.5 +/- 7.8 ng ml-1) compared with the Chinese (85.9 +/- 11.0 ng ml-1) and the Indian (58.2 +/- 3.0 ng ml-1) groups.,"Disposition of pethidine in man under acidic urinary pH. 4. Kinetics after oral dose in caucasian, Chinese and Indian subjects. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2314154/),[ng] / [ml],95.5,222934,DB00454,Pethidine
,2314154,Cmax,No significant difference was observed in their respective lag time while the absorption t1/2 was significantly shortest in the Caucasian group who also had the highest Cmax (95.5 +/- 7.8 ng ml-1) compared with the Chinese (85.9 +/- 11.0 ng ml-1) and the Indian (58.2 +/- 3.0 ng ml-1) groups.,"Disposition of pethidine in man under acidic urinary pH. 4. Kinetics after oral dose in caucasian, Chinese and Indian subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2314154/),[ng] / [ml],95.5,222935,DB00454,Pethidine
,2314154,Cmax,No significant difference was observed in their respective lag time while the absorption t1/2 was significantly shortest in the Caucasian group who also had the highest Cmax (95.5 +/- 7.8 ng ml-1) compared with the Chinese (85.9 +/- 11.0 ng ml-1) and the Indian (58.2 +/- 3.0 ng ml-1) groups.,"Disposition of pethidine in man under acidic urinary pH. 4. Kinetics after oral dose in caucasian, Chinese and Indian subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2314154/),[ng] / [ml],85.9,222936,DB00454,Pethidine
,2314154,Cmax,No significant difference was observed in their respective lag time while the absorption t1/2 was significantly shortest in the Caucasian group who also had the highest Cmax (95.5 +/- 7.8 ng ml-1) compared with the Chinese (85.9 +/- 11.0 ng ml-1) and the Indian (58.2 +/- 3.0 ng ml-1) groups.,"Disposition of pethidine in man under acidic urinary pH. 4. Kinetics after oral dose in caucasian, Chinese and Indian subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2314154/),[ng] / [ml],58.2,222937,DB00454,Pethidine
,2314154,elimination t1/2,"No significant difference was observed in the elimination t1/2 of pethidine between the Caucasian (8.3 +/- 0.2 h) and the Chinese (8.2 +/- 0.2 h) groups, although the Indian subjects significantly had the longest elimination t1/2 (0.1 +/- 0.3 h); this could possibly be due to their significantly higher apparent volume distribution.","Disposition of pethidine in man under acidic urinary pH. 4. Kinetics after oral dose in caucasian, Chinese and Indian subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2314154/),h,8.3,222938,DB00454,Pethidine
,2314154,elimination t1/2,"No significant difference was observed in the elimination t1/2 of pethidine between the Caucasian (8.3 +/- 0.2 h) and the Chinese (8.2 +/- 0.2 h) groups, although the Indian subjects significantly had the longest elimination t1/2 (0.1 +/- 0.3 h); this could possibly be due to their significantly higher apparent volume distribution.","Disposition of pethidine in man under acidic urinary pH. 4. Kinetics after oral dose in caucasian, Chinese and Indian subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2314154/),h,8.2,222939,DB00454,Pethidine
,2314154,elimination t1/2,"No significant difference was observed in the elimination t1/2 of pethidine between the Caucasian (8.3 +/- 0.2 h) and the Chinese (8.2 +/- 0.2 h) groups, although the Indian subjects significantly had the longest elimination t1/2 (0.1 +/- 0.3 h); this could possibly be due to their significantly higher apparent volume distribution.","Disposition of pethidine in man under acidic urinary pH. 4. Kinetics after oral dose in caucasian, Chinese and Indian subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2314154/),h,0.1,222940,DB00454,Pethidine
,11684406,recovery,The mean recovery of the drug from plasma samples was 95.71+/-2.82%.,Determination of pethidine in rabbit plasma by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11684406/),%,95.71,224780,DB00454,Pethidine
,6953738,plasma clearance,The plasma clearance of pethidine was significantly lower in the preoperative study (8.9 +/- 1.8 ml x kg x min-1) compared with the postoperative study (12.0 +/- 3.1 ml x kg x min-1).,Pharmacokinetics of pethidine during anaesthesia and patient-controlled analgesic therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953738/),[kg·ml] / [min],8.9,228662,DB00454,Pethidine
,6953738,plasma clearance,The plasma clearance of pethidine was significantly lower in the preoperative study (8.9 +/- 1.8 ml x kg x min-1) compared with the postoperative study (12.0 +/- 3.1 ml x kg x min-1).,Pharmacokinetics of pethidine during anaesthesia and patient-controlled analgesic therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953738/),[kg·ml] / [min],12.0,228663,DB00454,Pethidine
,6953738,Volume of distribution (Vd),"Volume of distribution (Vd) was not significantly influenced, being 4.25 +/- 1.72 l x kg-1 peroperatively and 3.14 +/- 0.84 l x kg-1 postoperatively.",Pharmacokinetics of pethidine during anaesthesia and patient-controlled analgesic therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953738/),[l] / [kg],4.25,228664,DB00454,Pethidine
,6953738,Volume of distribution (Vd),"Volume of distribution (Vd) was not significantly influenced, being 4.25 +/- 1.72 l x kg-1 peroperatively and 3.14 +/- 0.84 l x kg-1 postoperatively.",Pharmacokinetics of pethidine during anaesthesia and patient-controlled analgesic therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953738/),[l] / [kg],3.14,228665,DB00454,Pethidine
,6953738,Elimination half-life,Elimination half-life decreased from 5.91 +/- 3.57 h peroperatively to 3.25 +/- 1.40 h postoperatively.,Pharmacokinetics of pethidine during anaesthesia and patient-controlled analgesic therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953738/),h,5.91,228666,DB00454,Pethidine
,6953738,Elimination half-life,Elimination half-life decreased from 5.91 +/- 3.57 h peroperatively to 3.25 +/- 1.40 h postoperatively.,Pharmacokinetics of pethidine during anaesthesia and patient-controlled analgesic therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953738/),h,3.25,228667,DB00454,Pethidine
,6953738,fraction of unbound pethidine,The fraction of unbound pethidine decreased from 0.26 +/- 0.1 peroperatively to 0.18 +/- 0.1 postoperatively.,Pharmacokinetics of pethidine during anaesthesia and patient-controlled analgesic therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953738/),,0.26,228668,DB00454,Pethidine
,6953738,fraction of unbound pethidine,The fraction of unbound pethidine decreased from 0.26 +/- 0.1 peroperatively to 0.18 +/- 0.1 postoperatively.,Pharmacokinetics of pethidine during anaesthesia and patient-controlled analgesic therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953738/),,0.18,228669,DB00454,Pethidine
not exceed,6953738,plasma concentrations,Norpethidine plasma concentrations did not exceed 500 ng/ml.,Pharmacokinetics of pethidine during anaesthesia and patient-controlled analgesic therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6953738/),[ng] / [ml],500,228670,DB00454,Pethidine
,2384904,elimination half life,"When the drug was given intravenously to dogs suffering from intrahepatic shunts, the elimination half life was 75.5 +/- 4.2 min and the clearance rate was 29.0 +/- 2.3 ml/kg min.",The effect of clinical hepatic disease on the distribution and elimination of pethidine administered post-operatively to dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384904/),min,75.5,229851,DB00454,Pethidine
,2384904,clearance rate,"When the drug was given intravenously to dogs suffering from intrahepatic shunts, the elimination half life was 75.5 +/- 4.2 min and the clearance rate was 29.0 +/- 2.3 ml/kg min.",The effect of clinical hepatic disease on the distribution and elimination of pethidine administered post-operatively to dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384904/),[ml] / [kg·min],29.0,229852,DB00454,Pethidine
,2384904,rate of absorption,When the drug was given intramuscularly its rate of absorption was very slow (57.9 +/- 6.1 min) and the time taken to reach the maximum plasma concentration was long at 26.7 +/- 6.4 min.,The effect of clinical hepatic disease on the distribution and elimination of pethidine administered post-operatively to dogs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384904/),min,57.9,229853,DB00454,Pethidine
,2384904,time taken to reach the maximum plasma concentration,When the drug was given intramuscularly its rate of absorption was very slow (57.9 +/- 6.1 min) and the time taken to reach the maximum plasma concentration was long at 26.7 +/- 6.4 min.,The effect of clinical hepatic disease on the distribution and elimination of pethidine administered post-operatively to dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384904/),min,26.7,229854,DB00454,Pethidine
,2384904,elimination half-life,"The elimination half-life for the intramuscularly administered drug was also very slow at 108.0 +/- 13 min, reflecting the reduced ability of these dogs to metabolize and eliminate pethidine.",The effect of clinical hepatic disease on the distribution and elimination of pethidine administered post-operatively to dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384904/),min,108.0,229855,DB00454,Pethidine
,8839904,serum half-life,The serum half-life of tecogalan sodium was between 1-1.5 hours and < 25% of unchanged drug was excreted in the urine.,"A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839904/),h,1-1.5,230497,DB00454,Pethidine
,1424407,elimination half-life,"The pharmacokinetics of meperidine varied greatly between the subjects, with a median elimination half-life of 10.7 hours (range, 3.3 to 59.4 hours), median clearance of 8.0 ml/kg/min (range, 1.8 to 34.9 ml/kg/min), median volume of the central compartment of 2.4 L/kg (range, 0.5 to 4.8 L/kg), and median steady-state volume of distribution 7.2 L/kg (range, 3.3 to 11.0).",Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424407/),h,10.7,235274,DB00454,Pethidine
,1424407,clearance,"The pharmacokinetics of meperidine varied greatly between the subjects, with a median elimination half-life of 10.7 hours (range, 3.3 to 59.4 hours), median clearance of 8.0 ml/kg/min (range, 1.8 to 34.9 ml/kg/min), median volume of the central compartment of 2.4 L/kg (range, 0.5 to 4.8 L/kg), and median steady-state volume of distribution 7.2 L/kg (range, 3.3 to 11.0).",Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424407/),[ml] / [kg·min],8.0,235275,DB00454,Pethidine
,1424407,volume of the central compartment,"The pharmacokinetics of meperidine varied greatly between the subjects, with a median elimination half-life of 10.7 hours (range, 3.3 to 59.4 hours), median clearance of 8.0 ml/kg/min (range, 1.8 to 34.9 ml/kg/min), median volume of the central compartment of 2.4 L/kg (range, 0.5 to 4.8 L/kg), and median steady-state volume of distribution 7.2 L/kg (range, 3.3 to 11.0).",Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424407/),[l] / [kg],2.4,235276,DB00454,Pethidine
,1424407,steady-state volume of distribution,"The pharmacokinetics of meperidine varied greatly between the subjects, with a median elimination half-life of 10.7 hours (range, 3.3 to 59.4 hours), median clearance of 8.0 ml/kg/min (range, 1.8 to 34.9 ml/kg/min), median volume of the central compartment of 2.4 L/kg (range, 0.5 to 4.8 L/kg), and median steady-state volume of distribution 7.2 L/kg (range, 3.3 to 11.0).",Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424407/),[l] / [kg],7.2,235277,DB00454,Pethidine
,3358885,total plasma clearance,3. The mean total plasma clearance was 810 ml min-1 and the volume of distribution was 3.11 kg-1.,Pulmonary disposition of pethidine in postoperative patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358885/),[ml] / [min],810,235442,DB00454,Pethidine
,3358885,volume of distribution,3. The mean total plasma clearance was 810 ml min-1 and the volume of distribution was 3.11 kg-1.,Pulmonary disposition of pethidine in postoperative patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358885/),1/[kg],3.11,235443,DB00454,Pethidine
,7914736,blood clearance,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),[ml] / [kg·min],29.8,240059,DB00454,Pethidine
,7914736,volume of distribution,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),[l] / [kg],3.60,240060,DB00454,Pethidine
,7914736,blood elimination half-life,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),min,144,240061,DB00454,Pethidine
,2333432,elimination half-life,"When the drug was given intravenously (2 mg kg-1), plasma levels declined in a biexponential manner, with an elimination half-life of 62.7 minutes.",Pharmacokinetics of pethidine administered intramuscularly and intravenously to dogs over 10 years old. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333432/),min,62.7,240830,DB00454,Pethidine
,2333432,t 1/2 beta',The elimination of the intramuscularly administered drug was also slow with a t 1/2 beta' of 145.9 minutes.,Pharmacokinetics of pethidine administered intramuscularly and intravenously to dogs over 10 years old. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333432/),min,145.9,240831,DB00454,Pethidine
,2729638,maximal plasma concentration,The maximal plasma concentration was 341 +/- 133 ng.,Arterial and ventricular CSF pharmacokinetics after intrathecal meperidine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729638/),ng,341,242447,DB00454,Pethidine
,2729638,ventricular CSF-plasma ratio,The ventricular CSF-plasma ratio increased with time (r = 0.82) from 0.18 +/- 0.04 at the first hour to 0.38 +/- 0.1 at 16th hour.,Arterial and ventricular CSF pharmacokinetics after intrathecal meperidine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729638/),,0.18,242448,DB00454,Pethidine
,2729638,ventricular CSF-plasma ratio,The ventricular CSF-plasma ratio increased with time (r = 0.82) from 0.18 +/- 0.04 at the first hour to 0.38 +/- 0.1 at 16th hour.,Arterial and ventricular CSF pharmacokinetics after intrathecal meperidine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729638/),,0.38,242449,DB00454,Pethidine
,23870842,plasma clearance,"The plasma clearance and extraction ratios of meperidine were 22.7 ± 9.8 mL/minute and 10.1 ± 5.6% and for normeperidine 26.0 ± 11.4 mL/minute and 10.8 ± 2.5%, respectively.",Clearance of meperidine and its metabolite normeperidine in hemodialysis patients with chronic noncancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23870842/),[ml] / [min],22.7,243368,DB00454,Pethidine
,23870842,plasma clearance,"The plasma clearance and extraction ratios of meperidine were 22.7 ± 9.8 mL/minute and 10.1 ± 5.6% and for normeperidine 26.0 ± 11.4 mL/minute and 10.8 ± 2.5%, respectively.",Clearance of meperidine and its metabolite normeperidine in hemodialysis patients with chronic noncancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23870842/),[ml] / [min],26.0,243369,DB00454,Pethidine
,23870842,extraction ratios,"The plasma clearance and extraction ratios of meperidine were 22.7 ± 9.8 mL/minute and 10.1 ± 5.6% and for normeperidine 26.0 ± 11.4 mL/minute and 10.8 ± 2.5%, respectively.",Clearance of meperidine and its metabolite normeperidine in hemodialysis patients with chronic noncancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23870842/),%,10.1,243370,DB00454,Pethidine
,23870842,extraction ratios,"The plasma clearance and extraction ratios of meperidine were 22.7 ± 9.8 mL/minute and 10.1 ± 5.6% and for normeperidine 26.0 ± 11.4 mL/minute and 10.8 ± 2.5%, respectively.",Clearance of meperidine and its metabolite normeperidine in hemodialysis patients with chronic noncancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23870842/),%,10.8,243371,DB00454,Pethidine
,10809341,maximum concentration,Mean +/- SD maximum concentration was decreased from 126+/-47 to 51+/-21 ng/ml.,The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10809341/),[ng] / [ml],126,251687,DB00454,Pethidine
,10809341,maximum concentration,Mean +/- SD maximum concentration was decreased from 126+/-47 to 51+/-21 ng/ml.,The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10809341/),[ng] / [ml],51,251688,DB00454,Pethidine
,3697812,peak plasma concentration,The peak plasma concentration of meperidine was 175 +/- 78.8 ng X ml-1 (mean +/- SD) and this occurred 90 minutes after intrathecal injection.,Pharmacokinetics of meperidine in spinal anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697812/),[ng] / [ml],175,252510,DB00454,Pethidine
,3697812,terminal elimination half life of meperidine (t 1/2 beta),The terminal elimination half life of meperidine (t 1/2 beta) in the plasma was 198 minutes.,Pharmacokinetics of meperidine in spinal anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697812/),min,198,252511,DB00454,Pethidine
,3697812,duration of sensory,The mean duration of sensory and motor block was 77 +/- 18.8 and 47 +/- 7.4 minutes respectively.,Pharmacokinetics of meperidine in spinal anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697812/),min,77,252512,DB00454,Pethidine
,3697812,duration of sensory,The mean duration of sensory and motor block was 77 +/- 18.8 and 47 +/- 7.4 minutes respectively.,Pharmacokinetics of meperidine in spinal anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697812/),min,47,252513,DB00454,Pethidine
,3697812,motor,The mean duration of sensory and motor block was 77 +/- 18.8 and 47 +/- 7.4 minutes respectively.,Pharmacokinetics of meperidine in spinal anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697812/),min,77,252514,DB00454,Pethidine
,3697812,motor,The mean duration of sensory and motor block was 77 +/- 18.8 and 47 +/- 7.4 minutes respectively.,Pharmacokinetics of meperidine in spinal anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697812/),min,47,252515,DB00454,Pethidine
,2275236,apparent volume of distribution,Ketorolac is more than 99 percent bound to plasma proteins and has a mean apparent volume of distribution of 0.11-0.25 L/kg.,Ketorolac: a parenteral nonsteroidal antiinflammatory drug. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2275236/),[l] / [kg],0.11-0.25,255157,DB00454,Pethidine
,6546839,duration of analgesia,"Administration of morphine at the end of the operation resulted in a highly variable duration of analgesia ranging from 1-20.5 and 1-40 h for the 0.25 and 0.50 mg groups, respectively.",Pharmacokinetic aspects of intrathecal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),h,1-20.5,265271,DB00454,Pethidine
,6546839,duration of analgesia,"Administration of morphine at the end of the operation resulted in a highly variable duration of analgesia ranging from 1-20.5 and 1-40 h for the 0.25 and 0.50 mg groups, respectively.",Pharmacokinetic aspects of intrathecal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),h,1-40,265272,DB00454,Pethidine
,6546839,CSF,"Thus, at 1 h, CSF concentrations (means +/- SEM) were 4,228 +/- 361 ng/ml and 10,447 +/- 1,538 ng/ml for the 0.25 and 0.50-mg groups, respectively.",Pharmacokinetic aspects of intrathecal morphine analgesia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[ng] / [ml],"4,228",265273,DB00454,Pethidine
,6546839,CSF,"Thus, at 1 h, CSF concentrations (means +/- SEM) were 4,228 +/- 361 ng/ml and 10,447 +/- 1,538 ng/ml for the 0.25 and 0.50-mg groups, respectively.",Pharmacokinetic aspects of intrathecal morphine analgesia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[ng] / [ml],"10,447",265274,DB00454,Pethidine
,6546839,concentrations,"Thus, at 1 h, CSF concentrations (means +/- SEM) were 4,228 +/- 361 ng/ml and 10,447 +/- 1,538 ng/ml for the 0.25 and 0.50-mg groups, respectively.",Pharmacokinetic aspects of intrathecal morphine analgesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[ng] / [ml],"4,228",265275,DB00454,Pethidine
,6546839,concentrations,"Thus, at 1 h, CSF concentrations (means +/- SEM) were 4,228 +/- 361 ng/ml and 10,447 +/- 1,538 ng/ml for the 0.25 and 0.50-mg groups, respectively.",Pharmacokinetic aspects of intrathecal morphine analgesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[ng] / [ml],"10,447",265276,DB00454,Pethidine
,6546839,terminal elimination half-life,"For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM).",Pharmacokinetic aspects of intrathecal morphine analgesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),min,175,265277,DB00454,Pethidine
,6546839,terminal elimination half-life,"For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM).",Pharmacokinetic aspects of intrathecal morphine analgesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),min,196,265278,DB00454,Pethidine
,6546839,volume of CSF distribution,"For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM).",Pharmacokinetic aspects of intrathecal morphine analgesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[ml] / [kg],0.88,265279,DB00454,Pethidine
,6546839,volume of CSF distribution,"For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM).",Pharmacokinetic aspects of intrathecal morphine analgesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[ml] / [kg],1.06,265280,DB00454,Pethidine
,6546839,clearance from CSF,"For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM).",Pharmacokinetic aspects of intrathecal morphine analgesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[μl] / [kg·min],2.81,265281,DB00454,Pethidine
,6546839,clearance from CSF,"For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM).",Pharmacokinetic aspects of intrathecal morphine analgesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6546839/),[μl] / [kg·min],3.41,265282,DB00454,Pethidine
,7215421,plasma half-life (t1/2),"Following intravenous administration, the disposition of ketobemidone followed a biexponential pattern with a fast distribution phase and a slower elimination phase: the plasma half-life (t1/2) was 2.42 +/- 0.41 h (m +/- SD).",Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215421/),h,2.42,265300,DB00454,Pethidine
,7215421,elimination half-life,The elimination half-life was 3.27 +/- 0.32 h.,Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215421/),h,3.27,265301,DB00454,Pethidine
,7215421,bioavailability,The mean rectal bioavailability for ketobemidone was 44% +/- 9%.,Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215421/),%,44,265302,DB00454,Pethidine
,7215421,plasma half-life,"The plasma half-life was 3.07 +/- 0.53 h and 3.79 +/- 1.14 h, respectively.",Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215421/),h,3.07,265303,DB00454,Pethidine
,7215421,plasma half-life,"The plasma half-life was 3.07 +/- 0.53 h and 3.79 +/- 1.14 h, respectively.",Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215421/),h,3.79,265304,DB00454,Pethidine
,7215421,re,The rectal bioavailability was estimated to be 33% +/- 14%.,Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215421/),%,33,265305,DB00454,Pethidine
,7215421,bioavailability,The rectal bioavailability was estimated to be 33% +/- 14%.,Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215421/),%,33,265306,DB00454,Pethidine
,7094988,plasma clearance,"In comparison with the young the old patients had a lower plasma clearance for pethidine (9.13 +/- 2.50 versus 16.18 +/- 5.15 ml/min/kg), slower elimination rate beta (0.101 +/- 0.036 versus 0.211 +/- 0.146), and a larger AUC (1935 +/- 554 versus 1092 +/- 277 h . ng/ml) but a similar volume of distribution (5.69 +/- 1.54 versus 5.38 +/- 1.75 l/kg).",Comparative disposition of pethidine and norpethidine in old and young patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094988/),[ml] / [kg·min],9.13,270245,DB00454,Pethidine
,7094988,plasma clearance,"In comparison with the young the old patients had a lower plasma clearance for pethidine (9.13 +/- 2.50 versus 16.18 +/- 5.15 ml/min/kg), slower elimination rate beta (0.101 +/- 0.036 versus 0.211 +/- 0.146), and a larger AUC (1935 +/- 554 versus 1092 +/- 277 h . ng/ml) but a similar volume of distribution (5.69 +/- 1.54 versus 5.38 +/- 1.75 l/kg).",Comparative disposition of pethidine and norpethidine in old and young patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094988/),[ml] / [kg·min],16.18,270246,DB00454,Pethidine
,7094988,elimination rate beta,"In comparison with the young the old patients had a lower plasma clearance for pethidine (9.13 +/- 2.50 versus 16.18 +/- 5.15 ml/min/kg), slower elimination rate beta (0.101 +/- 0.036 versus 0.211 +/- 0.146), and a larger AUC (1935 +/- 554 versus 1092 +/- 277 h . ng/ml) but a similar volume of distribution (5.69 +/- 1.54 versus 5.38 +/- 1.75 l/kg).",Comparative disposition of pethidine and norpethidine in old and young patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094988/),,0.101,270247,DB00454,Pethidine
,7094988,elimination rate beta,"In comparison with the young the old patients had a lower plasma clearance for pethidine (9.13 +/- 2.50 versus 16.18 +/- 5.15 ml/min/kg), slower elimination rate beta (0.101 +/- 0.036 versus 0.211 +/- 0.146), and a larger AUC (1935 +/- 554 versus 1092 +/- 277 h . ng/ml) but a similar volume of distribution (5.69 +/- 1.54 versus 5.38 +/- 1.75 l/kg).",Comparative disposition of pethidine and norpethidine in old and young patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094988/),,0.211,270248,DB00454,Pethidine
,7094988,AUC,"In comparison with the young the old patients had a lower plasma clearance for pethidine (9.13 +/- 2.50 versus 16.18 +/- 5.15 ml/min/kg), slower elimination rate beta (0.101 +/- 0.036 versus 0.211 +/- 0.146), and a larger AUC (1935 +/- 554 versus 1092 +/- 277 h . ng/ml) but a similar volume of distribution (5.69 +/- 1.54 versus 5.38 +/- 1.75 l/kg).",Comparative disposition of pethidine and norpethidine in old and young patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094988/),[h·ng] / [ml],1935,270249,DB00454,Pethidine
,7094988,AUC,"In comparison with the young the old patients had a lower plasma clearance for pethidine (9.13 +/- 2.50 versus 16.18 +/- 5.15 ml/min/kg), slower elimination rate beta (0.101 +/- 0.036 versus 0.211 +/- 0.146), and a larger AUC (1935 +/- 554 versus 1092 +/- 277 h . ng/ml) but a similar volume of distribution (5.69 +/- 1.54 versus 5.38 +/- 1.75 l/kg).",Comparative disposition of pethidine and norpethidine in old and young patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094988/),[h·ng] / [ml],1092,270250,DB00454,Pethidine
,7094988,volume of distribution,"In comparison with the young the old patients had a lower plasma clearance for pethidine (9.13 +/- 2.50 versus 16.18 +/- 5.15 ml/min/kg), slower elimination rate beta (0.101 +/- 0.036 versus 0.211 +/- 0.146), and a larger AUC (1935 +/- 554 versus 1092 +/- 277 h . ng/ml) but a similar volume of distribution (5.69 +/- 1.54 versus 5.38 +/- 1.75 l/kg).",Comparative disposition of pethidine and norpethidine in old and young patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094988/),[l] / [kg],5.69,270251,DB00454,Pethidine
,7094988,volume of distribution,"In comparison with the young the old patients had a lower plasma clearance for pethidine (9.13 +/- 2.50 versus 16.18 +/- 5.15 ml/min/kg), slower elimination rate beta (0.101 +/- 0.036 versus 0.211 +/- 0.146), and a larger AUC (1935 +/- 554 versus 1092 +/- 277 h . ng/ml) but a similar volume of distribution (5.69 +/- 1.54 versus 5.38 +/- 1.75 l/kg).",Comparative disposition of pethidine and norpethidine in old and young patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094988/),[l] / [kg],5.38,270252,DB00454,Pethidine
,11903869,elimination half-life (t1/2el),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,76.3,270824,DB00454,Pethidine
,11903869,elimination half-life (t1/2el),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,93.6,270825,DB00454,Pethidine
,11903869,mean residence time (MRT),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,105.0,270826,DB00454,Pethidine
,11903869,mean residence time (MRT),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,120.5,270827,DB00454,Pethidine
,11903869,clearance (Clp),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],24.1,270828,DB00454,Pethidine
,11903869,clearance (Clp),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],13.9,270829,DB00454,Pethidine
,11903869,volume of distribution (V(dss)),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],2.6,270830,DB00454,Pethidine
,11903869,volume of distribution (V(dss)),"Our data for morphine show elimination half-life (t1/2el) 76.3 min intravenous (i.v.) and 93.6 min intramuscular (i.m.); mean residence time (MRT) 105.0 and 120.5 min; clearance (Clp) 24.1 and 13.9 mL/kg/min; and volume of distribution (V(dss)) 2.6 and 1.7 L/kg, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],1.7,270831,DB00454,Pethidine
,11903869,t1/2el,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,416.8,270832,DB00454,Pethidine
,11903869,t1/2el,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,380.2,270833,DB00454,Pethidine
,11903869,MRT,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,417.6,270834,DB00454,Pethidine
,11903869,MRT,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,409.8,270835,DB00454,Pethidine
,11903869,Clp,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],16.7,270836,DB00454,Pethidine
,11903869,Clp,Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],23.7,270837,DB00454,Pethidine
,11903869,V(dss),Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],7.1,270838,DB00454,Pethidine
,11903869,V(dss),Comparable data for buprenorphine are t1/2el 416.8 and 380.2 min; MRT 417.6 and 409.8 min; Clp 16.7 and 23.7 mL/kg/min; and V(dss) 7.1 and 8.9 L/kg.,"Morphine, pethidine and buprenorphine disposition in the cat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],8.9,270839,DB00454,Pethidine
,11903869,t1/2el,"For i.m. pethidine, t1/2el 216.4 min; MRT 307.5 min; Clp 20.8 mL/kg/min and V(dss) 5.2 L/kg.","Morphine, pethidine and buprenorphine disposition in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,216.4,270840,DB00454,Pethidine
,11903869,MRT,"For i.m. pethidine, t1/2el 216.4 min; MRT 307.5 min; Clp 20.8 mL/kg/min and V(dss) 5.2 L/kg.","Morphine, pethidine and buprenorphine disposition in the cat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,307.5,270841,DB00454,Pethidine
,11903869,Clp,"For i.m. pethidine, t1/2el 216.4 min; MRT 307.5 min; Clp 20.8 mL/kg/min and V(dss) 5.2 L/kg.","Morphine, pethidine and buprenorphine disposition in the cat. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[ml] / [kg·min],20.8,270842,DB00454,Pethidine
,11903869,V(dss),"For i.m. pethidine, t1/2el 216.4 min; MRT 307.5 min; Clp 20.8 mL/kg/min and V(dss) 5.2 L/kg.","Morphine, pethidine and buprenorphine disposition in the cat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),[l] / [kg],5.2,270843,DB00454,Pethidine
,11903869,tmax,"For i.m. dosing, the tmax for morphine, buprenorphine and pethidine were 15, 3 and 10 min, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,15,270844,DB00454,Pethidine
,11903869,tmax,"For i.m. dosing, the tmax for morphine, buprenorphine and pethidine were 15, 3 and 10 min, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,3,270845,DB00454,Pethidine
,11903869,tmax,"For i.m. dosing, the tmax for morphine, buprenorphine and pethidine were 15, 3 and 10 min, respectively.","Morphine, pethidine and buprenorphine disposition in the cat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903869/),min,10,270846,DB00454,Pethidine
,9604855,bioavailability,"The Fel (fraction eliminated unchanged in urine) was calculated from the amount excreted in 36 h in urine and dose, assuming a bioavailability of 1 based on literature data.",Urinary excretion of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9604855/),,1,272716,DB00454,Pethidine
